{
  "0EH.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Toleranzia AB",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TOLERANZIA AB",
    "state": null,
    "summary": "Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. The company is headquartered in Gothenburg, Sweden.",
    "website": "http://www.toleranzia.com",
    "zipcode": "411 26"
  },
  "10B.MU": {
    "city": "Kista",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "MUN",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Bioservo Technologies AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOSERVO TECHNOLAB",
    "state": null,
    "summary": "Bioservo Technologies AB (publ) develops wearable muscle strengthening systems worldwide. It offers Ironhand, a robotic muscle strengthening system for professional applications; and Carbonhand, a grip enhancing device that facilitates a normal movement pattern for use in healthcare applications. Bioservo Technologies AB (publ) was founded in 2006 and is based in Kista, Sweden.",
    "website": "http://www.bioservo.com",
    "zipcode": "164 40"
  },
  "16E.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Episurf Medical AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EPISURF MEDICAL AB B",
    "state": null,
    "summary": "Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in the Nordic countries, Benelux, Germany, the United Kingdom, and internationally. The company offers Episealer Condyle Solo for the treatment of localized cartilage and underlying bone defects on the femoral condyles of the knee joint; Episealer Trochlea Solo to treat localized cartilage and underlying bone defects in the area behind the patella; and Episealer Femoral Twin for the treatment of elongated localized cartilage and underlying bone defects on the femoral condyles and in the trochlea area of the knee joint. It also provides Episealer Talus for osteochondral lesions of the talar dome of the ankle joint; and Epiguide, a patient-specific drill guide for the treatment of painful joints. In addition, the company offers ÂµiFidelity system, a web-based IT platform for damage assessment, surgical pre-planning, and patient customization of implants and related surgical instruments; and Epioscopy, a damage assessment tool. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.",
    "website": "http://episurf.com",
    "zipcode": "114 49"
  },
  "1AD1.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "AddLife AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ADDLIFE AB B",
    "state": null,
    "summary": "AddLife AB (publ), together with its subsidiaries, supplies equipment, instruments, and reagents to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries in Sweden, Finland, Denmark, Norway, and internationally. The company operates through two segments, Labtech and Medtech. The Labtech segment provides analysis instruments, equipment, microscopes, consumables and reagents, as well as software support and technical services primarily to laboratories in medicine, research, academia, food, pharmaceutical, microbiology, clinical chemistry, coagulation, molecular biology, immunology, point-of-care testing, and veterinary diagnostics industries. This segment also offers training programs, seminars, and advisory services. The Medtech segment provides medical device products to surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ear, nose and throat, ostomies, and home healthcare markets. AddLife AB (publ) was founded in 1906 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.add.life",
    "zipcode": "103 62"
  },
  "1DO.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Doxa AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "DOXA AB (PUBL)",
    "state": null,
    "summary": "Doxa AB (publ), a dental company, develops, manufactures, and commercializes bioceramic dental products under the Ceramir brand worldwide. It offers Crown & Bridge, a dental cement that is used for permanent cementing of crowns and bridges. The company was founded in 1987 and is based in Uppsala, Sweden.",
    "website": "http://www.doxa.se",
    "zipcode": "754 50"
  },
  "1XT.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Xintela AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "XINTELA AB",
    "state": null,
    "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",
    "website": "http://www.xintela.se",
    "zipcode": "223 81"
  },
  "1YG.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immunicum AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMMUNICUM AB",
    "state": null,
    "summary": "Immunicum AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trial for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as has completed Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I ALISON clinical trial for the treatment of ovarian cancers. It has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study; and research collaboration with Icahn School of Medicine At Mount Sinai. The company is headquartered in Stockholm, Sweden.",
    "website": "http://immunicum.se",
    "zipcode": "114 42"
  },
  "1YR.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Immunovia AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMMUNOVIA AB",
    "state": null,
    "summary": "Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.",
    "website": "http://www.immunovia.com",
    "zipcode": "223 63"
  },
  "27R.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "RaySearch Laboratories AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RAYSEARCH LABS B  SK 0,40",
    "state": null,
    "summary": "RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in Sweden and internationally. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, reduce OAR dose, robustness, the physician's toolbox, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomo therapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomo therapy, and electron beam radiation therapy; and RayCare, an oncology information system for the treatment of cancer comprising oncology treatment activities, including digital oncology workflows, rule-based scheduling, state-of-the-art software platform, enterprise-wide integration, adaptive therapy, RayCare flow, and data handling and machine learning. In addition, it offers RayCommand, a treatment control system that is compatible with multiple hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system, which turns patient data into insights. Further, the company provides training courses, as well as customer support services. RaySearch Laboratories AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.raysearchlabs.com",
    "zipcode": "111 34"
  },
  "2B4.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Bonesupport Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BONESUPPORT HOLDING AB",
    "state": null,
    "summary": "Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes for the treatment of bone disorders in Sweden, rest of Europe, North America, and internationally. The company offers CERAMENT Bone Void Filler, a resorbable ceramic bone graft substitute used to fill gaps and voids in the skeletal system to promote bone healing; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It is also developing preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. The company's products are used in orthopedic markets. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.",
    "website": "http://www.bonesupport.com",
    "zipcode": "223 70"
  },
  "2BQ.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "GHP Specialty Care AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GHP SPECIALTY CARE AB SK1",
    "state": null,
    "summary": "GHP Specialty Care AB (publ) provides healthcare services in the Nordic region and internationally. The company operates specialist clinics that offer services in various areas, including orthopaedics, spine surgery/spine care, obesity surgery and diabetes care, gastroenterology, urology, general surgery, arrhythmia, sports medicine, neurology, skin, and specialist dentistry. It operates 22 specialty care clinics in the Nordic Region. The company was formerly known as Global Health Partner AB (publ) and changed its name to GHP Specialty Care AB (publ) in May 2015. GHP Specialty Care AB (publ) was founded in 2006 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.ghp.se",
    "zipcode": "411 06"
  },
  "2E9.F": {
    "city": "HÃ¤gersten",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Intervacc AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "INTERVACC AB",
    "state": null,
    "summary": "Intervacc AB (publ), a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. It offers vaccines, pharmaceuticals, and vitamins for horses, piglets, and cows. The company also provides veterinary bacteriological and mycological analyses for veterinarians and animal hospitals. It serves customers in Nordic countries and the Baltic states. Intervacc AB (publ) holds an agreement with the Swedish University of Agricultural Sciences, SLU for the development of animal health vaccines. The company is based in HÃ¤gersten, Sweden.",
    "website": "http://www.intervacc.se",
    "zipcode": "129 44"
  },
  "2FV.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "ScandiDos AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SCANDIDOS AB (PUBL)",
    "state": null,
    "summary": "ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family solution for pre treatment and at treatment dose verification covering various treatment technologies, such as VMAT, IMRT, SBRT, 4D-RT, and TomoTherapy; Delta4 Discover, a transmission detector that provides confidence and patient safety based on real time measurements; and Delta4 Phantom+, a system that offers accurate and verification of IMRT, VMAT, and TomoTherapy plans. It also provides HexaMotion, a motion management solution; Delta4DVH Anatomy, a software that verifies and analyzes the dose delivered in the patient anatomy; Delta4 Machine QA, a software to perform QA with respect to rotation, start-up behavior, and dynamic beam modulation; and Delta4 Trolley, an ergonomic solution. The company is headquartered in Uppsala, Sweden.",
    "website": "http://scandidos.com",
    "zipcode": "751 83"
  },
  "2HJ.F": {
    "city": "Kista",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Brighter AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BRIGHTER AB (PUBL)",
    "state": null,
    "summary": "Brighter AB (publ), a health-tech company, develops data-driven solutions for the treatment of chronic condition in Sweden. It is developing Actiste, a mobile-connected device to remotely monitor and treat insulin-dependent diabetes; and The Benefit Loop, a cloud-based platform that gathers, processes, analyzes, and organizes real-life data. The company offers its products to consumers and patients, mobile network operators, healthcare providers, governments/authorities, insurance companies, consumers, companies/employers, clinical research organizations, pharmaceutical companies, research and development organizations, authorities, and academic bodies. Brighter AB (publ) was founded in 2007 and is based in Kista, Sweden.",
    "website": "http://brighter.se",
    "zipcode": "164 32"
  },
  "2I9.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Karolinska Development AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KAROLINSKA DEVELOP.AB",
    "state": null,
    "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.karolinskadevelopment.com",
    "zipcode": "17165"
  },
  "2OK.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "SpectraCure AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SPECTRACURE AB",
    "state": null,
    "summary": "SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.",
    "website": "http://www.spectracure.com",
    "zipcode": "222 29"
  },
  "3EE0.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Kancera AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KANCERA AB",
    "state": null,
    "summary": "Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567 and KAND145 which block the Fractalkine receptor CX3CR1 and thus specific parts of the immune system for treatment of hyperinflammation HDAC6 for the treatment of nerve inflammation and pain; and ROR inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.",
    "website": "http://www.kancera.com",
    "zipcode": "171 65"
  },
  "3KT.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "Kontigo Care AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "KONTIGO CARE  AB",
    "state": null,
    "summary": "Kontigo Care AB (publ) provides health care solutions for addiction treatment in Sweden. It offers Previct Alcohol, a digital medical device for the drug rehabilitation; and Previct Gambling, a digital tool for the treatment and prevention of work at the gaming addiction. Kontigo Care AB (publ) was founded in 2013 and is based in Uppsala, Sweden.",
    "website": "http://www.kontigocare.com",
    "zipcode": null
  },
  "40M.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nanexa AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NANEXA AB",
    "state": null,
    "summary": "Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.",
    "website": "http://www.nanexa.com",
    "zipcode": "75450"
  },
  "47H.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Humana AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HUMANA AB",
    "state": null,
    "summary": "Humana AB (publ) provides individual and family care services for children, adolescents, and adults in Sweden, Finland, Norway, and Denmark. The company operates through Individual & Family, Personal Assistance, and Elderly Care segments. The Individual & Family segment provides care and treatment in psychiatry and psychosocial change management through residential care homes, temporary and regular family homes, special service housing, outpatient care and assisted living homes, and specially adapted housing. The Personal Assistance segment offers care services and assistance to individuals with functional impairments. The Elderly Care segment consists of elderly housing, as well as provides day care, flats adapted for the elderly, meeting places, and family member services. Humana AB (publ) was founded in 2001 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.humana.se",
    "zipcode": "112 51"
  },
  "49Z.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Cellink AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "CELLINK AB AK B  O.N.",
    "state": null,
    "summary": "Cellink AB (publ), a bio convergence company, designs and develops bioprinting, liquid handling, single-cell analysis, and live-cell imaging technologies in North America, Europe, Asia, and internationally. The company's bioprinting solutions include BIO MDX, bioprinting systems for biomedical manufacturing; BIO X, 3D bioprinter for cell biologists, tissue engineers and biomedical researchers; BIO X6, a 6 printhead 3D bioprinter; INKREDIBLE and INKREDIBLE+, which are 3D bioprinting solutions; Holograph X, provides ultra-high-resolution 3D bioprinting at the micrometer level using holographic stereolithography; and Lumen X, a solution that offers applications in microfluidics, cell-laden hydrogels, macroporous structures. It also offers C.BIRD, a microbioreactor for cell line development, as well as SOLARIS BIOREACTORS, a platforms for research and development, and product development applications; UP.SIGHT, a cell line development solution; Single-Cell Printer, an automated laboratory instrument; C.SIGHT, a single-cell dispensing technology for cell line development and single-cell genomics; B.SIGHT, a solution that enables prokaryotic cell isolation in the sub-micron range; and F.SIGHT, a solution that dispenses unlabeled and fluorescent cells. In addition, the company provides I-DOT, a solution for liquid-handling tasks; C.WASH, a plate washer; LIVECYTE, a kinetic cytometer; CELLCYTE X, a live cell imaging system; and CASY, a cell status monitoring solution, as well as open qPCR system and NGS reagents. Further, it offers consumables, and hand sanitizers and sanitizing wipes. The company serves universities, research organizations, pharmaceutical companies, and cosmetic and skin care companies, as well as packaging and automotive industries. It has strategic partnership with Made In Space for advancing bioprinting technology in space. The company also offers products online. Cellink AB (publ) was founded in 2016 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.cellink.com",
    "zipcode": "413 46"
  },
  "4CX.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Cyxone AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CYXONE AB  SK-,75",
    "state": null,
    "summary": "Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis; and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.cyxone.com",
    "zipcode": "221 22"
  },
  "4HG.F": {
    "city": "Helsingborg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Qlife Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "QLIFE HOLDING AB",
    "state": null,
    "summary": "Qlife Holding AB (publ), a high-tech medical device company, manufactures and sells in-vitro diagnostic analyzers and reagents. It offers Egoo Home System, an integrated platform consisting of a small home device and disposable capsules each of that test for a specific biomarker, as well as a digital infrastructure that shares data with patient journal or hospital platform. The company has a research agreement with NordsjÃ¦llands Hospital to continue the validation of the Egoo Sars-CoV-2 virus test. The company was founded in 2019 and is based in Helsingborg, Sweden.",
    "website": "http://qlifeholding.com/en",
    "zipcode": "252 21"
  },
  "4K4.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Stayble Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "STAYBLE THERAPEUTICS AB",
    "state": null,
    "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.",
    "website": "http://www.staybletherapeutics.se",
    "zipcode": "413 90"
  },
  "4SA.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "AcouSort AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACOUSORT AB O.N.",
    "state": null,
    "summary": "AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.",
    "website": "http://www.acousort.com",
    "zipcode": "223 81"
  },
  "4Z7.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "IRRAS AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IRRAS AB",
    "state": null,
    "summary": "IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. It designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. The company offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. It also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include Hummingbird Quad ICP monitoring with drainage (H610), and Hummingbird Solo ICP monitoring (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. The company markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was incorporated in 2011 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.irras.com",
    "zipcode": "111 20"
  },
  "50V.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "Aino Health AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AINO HEALTH AB O.N.",
    "state": null,
    "summary": "Aino Health AB (publ) provides corporate health management solutions for private and public organizations in Finland. It offers HealthManager, a software as a service solution that provides surveys, analytics, exposure checks, and security and GDPR services; and e-learning platform. The company also provides telemedicine services; professional services, including analytics, management and employee support, and well-being services; onboarding services, such as project management and planning, implementation, and training and communication services; and other services to occupational health care providers, insurance companies, IT software and service companies, HR, payroll service centers, nurses, online therapists, etc. Aino Health AB (publ) is based in Stockholm, Sweden.",
    "website": "http://www.ainohealth.com",
    "zipcode": "115 23"
  },
  "52Q.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "AegirBio AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "AEGIRBIO AB",
    "state": null,
    "summary": "Aegirbio AB, a diagnostic company, offers tests to monitor and optimize the dosage of biological drugs in Sweden. The company focuses on therapeutic drug monitoring of biologic therapies in the autoimmune, oncology, and neurology space. It offers moNATor, a first dose-monitoring laboratory test to multiple sclerosis for healthcare professionals and patients. The company is based in Lund, Sweden.",
    "website": "http://aegirbio.com",
    "zipcode": "223 70"
  },
  "52X.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Magle Chemoswed Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MAGLE CHEMOSWED HOLDING",
    "state": null,
    "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in MalmÃ¶, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.",
    "website": "http://www.maglechemoswed.cow",
    "zipcode": "212 15"
  },
  "5GV.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Genovis AB (publ.)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GENOVIS AB  SE-,40",
    "state": null,
    "summary": "Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.",
    "website": "http://www.genovis.com",
    "zipcode": "220 07"
  },
  "5IU.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Isofol Medical AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ISOFOL MEDICAL AB",
    "state": null,
    "summary": "Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, Solasia Pharma KK, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.",
    "website": "http://isofolmedical.com",
    "zipcode": "413 46"
  },
  "5J2.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Gabather AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GABATHER AB (PUBL) SK-,44",
    "state": null,
    "summary": "Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was founded in 2014 and is based in MalmÃ¶, Sweden.",
    "website": "http://www.gabather.com",
    "zipcode": "211 20"
  },
  "5J3.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "SciBase Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SCIBASE HOLDING AB",
    "state": null,
    "summary": "SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions.in Europe and internationally. The company offers Nevisense, a point-of-care detection device for non-visual detection of malignant melanoma. It serves public hospitals and private dermatology clinics. The company has a collaboration agreement with Swiss Institute of Allergy and Asthma Research. The company was founded in 1998 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.scibase.com",
    "zipcode": "172 63"
  },
  "5J6.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "OssDsign AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OSSDSIGN AB",
    "state": null,
    "summary": "OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. Its products include OSSDSIGN cranial, an implant solution for cranioplasty patients, as well as related accessories; OSSDSIGN facial to treat patients with complex facial skeletal defects; and OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage, as well as nanosynthetic bone graft substitute for treating skeletal defect. The company was incorporated in 2011 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.ossdsign.com",
    "zipcode": "754 50"
  },
  "5J9.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Fluicell AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "FLUICELL AB",
    "state": null,
    "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.",
    "website": "http://www.fluicell.com",
    "zipcode": "413 46"
  },
  "5JA1.F": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Sprint Bioscience AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SPRINT BIOSCIENCE AB",
    "state": null,
    "summary": "Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PIP4K2, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.",
    "website": "http://www.sprintbioscience.com",
    "zipcode": "141 57"
  },
  "5JE.F": {
    "city": "Tullinge",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Bactiguard Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BACTIGUARD HLDG B",
    "state": null,
    "summary": "Bactiguard Holding AB (publ), a medical device company, engages in the research and development, production, marketing, and sale of infection prevention solutions. Its infection prevention solutions prevent healthcare associated infections caused by medical devices. The company's products portfolio reduces the risk of infections in the urinary tract, the respiratory tract, and the bloodstream. Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter, which reduces the risk of biofilm formation and infection; BIP Endotracheal Tube that reduces the risk of infection; BIP Endotracheal Tube Evac, which is used to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that combines surveillance and infection prevention. The company's products also include Hydrocyn aqua advanced wound care, a wound wash, debridement, and irrigation solution for chronic and acute wounds; surgical sutures comprise of non-absorbable, natural absorbable, synthetic absorbable, and specialty sutures; VigiMesh, a sterile, non-absorbable, and knitted polypropylene monofilament mesh material for tissue reinforcement for use in hernia repair; and Hydrocyn aqua advanced disinfectant, a non-alcoholic disinfectant for skin and surfaces to kill bacteria, virus, and fungi. The company serves in the United States, Sweden, Malaysia, China, Thailand, Bangladesh, New Zealand, and internationally. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.",
    "website": "http://www.bactiguard.com",
    "zipcode": "146 21"
  },
  "5JK.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ISR Immune System Regulation Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ISR IMMUNE SYS.REGUL.HLDG",
    "state": null,
    "summary": "ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden. The company's product candidates include ISR048 that has completed Phase I/IIa clinical trial for the treatment of human immunodeficiency virus infection (HIV); and ISR049, which is in the development stage to treat HIV. It is also developing a second line of chemical entities, including ISR050 that has immunostimulatory properties. The company is headquartered in Stockholm, Sweden.",
    "website": "http://israb.se",
    "zipcode": "113 40"
  },
  "5LU.F": {
    "city": "HammenhÃ¶g",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Simris Alg AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SIMRIS ALG AB  B",
    "state": null,
    "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in HammenhÃ¶g, Sweden.",
    "website": "http://www.simrisalg.se",
    "zipcode": "276 50"
  },
  "5M0B.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Medicover AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "MEDICOVER AB",
    "state": null,
    "summary": "Medicover AB (publ) provides healthcare and diagnostic services in Germany, Germany, Romania, Ukraine, Poland, Belarus, Moldova, Serbia, Turkey, Georgia, Bulgaria, Sweden, India, Hungary, and internationally. It operates through two segment, Healthcare Services and Diagnostic Services. The company's diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. It offers outpatient and inpatient healthcare services, including fertility treatment centres, dental clinics, elderly care centres, eye care, and skin and wellness centres, as well as fitness and pharmacy solutions. The company operates 97 clinical laboratories, 733 blood-drawing points, and 26 clinics in 10 countries; and 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. It serves corporate and private customers, and patients, as well as public payers. The company was founded in 1995 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.medicover.com",
    "zipcode": "102 46"
  },
  "61LA.F": {
    "city": "LinkÃ¶ping",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Sectra AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SECTRA AB B(P.S.)SK 0,125",
    "state": null,
    "summary": "Sectra AB (publ) provides IT systems for managing medical images and patient information related to diagnostic imaging. The company's Imaging IT Solutions segment develops and sells medical IT systems and services for managing, archiving, and presenting various types of medical images and patient information, as well as for operational follow-up and radiation dose monitoring; maintenance services in the form of support and system monitoring; and consulting services related to integration, system design, data migration, and business development. Its Secure Communications segment develops and sells products and services for secure voice and data communications, and protection of society's sensitive IT infrastructure; customized encryption systems and products; and critical infrastructure, which offers security and threat analyses and system monitoring services for control systems in society's critical operations. The company's Business Innovation segment develops and sells IT systems for planning and monitoring orthopedic surgery; and products for medical education and research projects. It serves public and private healthcare providers comprising hospitals, and hospital and private clinic chains; and government agencies and defense departments. Sectra AB (publ) sells its products through its sales organizations and distribution partners in Africa, Europe, the Middle East, North America, Oceania, Southeast Asia, and Japan. The company was founded in 1978 and is headquartered in LinkÃ¶ping, Sweden.",
    "website": "http://www.sectra.com",
    "zipcode": "583 30"
  },
  "65G.F": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "NextCell Pharma AB",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEXTCELL PHARMA AB",
    "state": null,
    "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.",
    "website": "http://www.nextcellpharma.com",
    "zipcode": "141 57"
  },
  "6FN.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Klaria Pharma Holding AB (publ.)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "KLARIA PHARMA HOLDING AB",
    "state": null,
    "summary": "Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.",
    "website": "http://www.klaria.com",
    "zipcode": "754 50"
  },
  "6MA.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Ambea AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "AMBEA AB O.N.",
    "state": null,
    "summary": "Ambea AB (publ) provides residential care services for people with special needs in Sweden, Norway, and Denmark. The company operates through five segments: Vardaga, Nytida, Stendi, Altiden, and Klara. It offers permanent residential placements, short-term placements, relief care, and respite care services; home care services, including cleaning, washing, shopping, private nursing, cooking, walks, and companionship; child care homes, holiday camps, and short-term housing services; group homes, assisted living facilities, and day services; and support services, such as homes for care or residence, assisted living facilities, supported living facilities, foster homes, sheltered housing, non-residential care and assessments for children, young people, and adults. The company also provides day-care centers, elementary schools, special needs elementary schools, and special needs upper secondary schools for children and young people with neuropsychiatric disabilities; residential and care services for adults with disabilities, abuse problems, early-onset dementia, and mental health problems; short-break residential facilities for children and young people with disabilities; user-controlled personal assistance for children and adults; senior apartments, nursing homes, day centers, home care, and rehabilitation services for elderly people. In addition, it offers ambulatory care, emergency care team, and rehabilitation staff services; supplies temporary doctors, nurses, psychologists, and speech pathologists; and recruitment services for nurses and unit managers. Ambea AB (publ) was founded in 1996 and is headquartered in Solna, Sweden.",
    "website": "http://www.ambea.se",
    "zipcode": "171 29"
  },
  "6XA.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Olink Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "OLINK HOLDING AB SP.ADS/1",
    "state": null,
    "summary": "Olink Holding AB (publ) provides various products and services for academic, government, biopharmaceutical, biotechnology, and other institutions focused on life science research. Its products include Olink Explore for cardiovascular and metabolic diseases, oncology, neurology, or inflammation; Olink Target product line; and Olink Focus product line consists of custom developed solutions for customers that have identified a small number of proteins of interest to focus on. The company's products also comprise Olink NPX Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of normalized protein expression (NPX) data. In addition, it provides Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. The company sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2016 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.olink.com",
    "zipcode": "751 83"
  },
  "6XP.SG": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Xspray Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "XSpray Pharma AB Namn-Aktier o.",
    "state": null,
    "summary": "Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.",
    "website": "http://www.xspraypharma.com",
    "zipcode": "169 67"
  },
  "6Y1.F": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Integrum AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INTEGRUM AB B",
    "state": null,
    "summary": "Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company offers OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) implant system, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system provides protection to the patient by avoiding bone fractures from accidental loads. The company also offers Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. The company was founded in 1962 and is based in MÃ¶lndal, Sweden.",
    "website": "http://www.integrum.se",
    "zipcode": "431 37"
  },
  "6Y4.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Vicore Pharma Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "VICORE PHARMA HOLDING AB",
    "state": null,
    "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.vicorepharma.com",
    "zipcode": "411 05"
  },
  "6YC.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Senzime AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SENZIME AB AK",
    "state": null,
    "summary": "Senzime AB (publ) develps and markets patient monitoring systems to monitor patients under anesthesia in Europe and the United States. The company offers TetraGraph, a TOF-monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; CliniSenz Analyzer, which detects early signs of complications; and Onzurf Probe for sampling from the surface of an organ. Senzime AB (publ) was founded in 1999 and is based in Uppsala, Sweden.",
    "website": "http://www.senzime.com",
    "zipcode": "756 51"
  },
  "782.F": {
    "city": "VÃ¤sterÃ¥s",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Scandinavian Real Heart AB (Publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SCANDINAV. REAL HEART AB",
    "state": null,
    "summary": "Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. The company engages in developing total artificial heart that provides solutions to patients diagnosed with advanced congestive heart failure. It also develops Realheart VAD, Realheart PulsePump, and Realheart Sternal prosthetic products. The company was founded in 2007 and is based in VÃ¤sterÃ¥s, Sweden.",
    "website": "http://realheart.se",
    "zipcode": "722 13"
  },
  "78D.F": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Alzinova AB",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALZINOVA AB",
    "state": null,
    "summary": "Alzinova AB, a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic AÃ oligomers. The company was founded in 2011 and is based in MÃ¶lndal, Sweden.",
    "website": "http://www.alzinova.com",
    "zipcode": "431 83"
  },
  "7AC.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Acarix AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACARIX AB",
    "state": null,
    "summary": "Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases. The company offers CADScor System for the diagnosis of coronary artery disease. It operates in Germany, Sweden, Denmark, and internationally. Acarix AB (publ) was founded in 2009 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.acarix.com",
    "zipcode": "211 19"
  },
  "7AL.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Alligator Bioscience AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ALLIGATOR BIOSC. AB O.N.",
    "state": null,
    "summary": "Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in the United States, Sweden, Asia, and internationally. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial to treat metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://www.alligatorbioscience.se",
    "zipcode": "223 81"
  },
  "7AT.F": {
    "city": "Danderyd",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Attendo AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ATTENDO AB",
    "state": null,
    "summary": "Attendo AB (publ) provides financed care services in Sweden, Finland, Norway, and Denmark. The company offers care services for older people in nursing homes and home care. It also provides disabilities care services for people with disabilities, such as homes and supportive housing, daily activities, respite care, and short-term accommodation; and social psychiatry, and emergency shelters and family support homes for individuals and family. The company also operates group homes for adults, homes for children with special needs; consultant supported family home care services; crisis and acute accommodations; and substance abuse care services. It also offers home care services based on outsourcing contracts. Attendo AB (publ) was founded in 1985 and is headquartered in Danderyd, Sweden.",
    "website": "http://www.attendo.com",
    "zipcode": "182 91"
  },
  "7CA.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Camurus AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CAMURUS AB",
    "state": null,
    "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; and episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity. Its products pipeline also includes Brixadi for opioid dependence; CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension and Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4083 for treatment of myasthenia gravis and other serious tissue-based complement-mediated disorders; CAM2047 for the treatment of chemotherapy induced nausea and vomiting; and CAM2048 for postoperative pain. The company was founded in 1991 and is headquartered in Lund, Sweden.",
    "website": "http://www.camurus.com",
    "zipcode": "223 70"
  },
  "7D2.F": {
    "city": "Danderyd",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Sedana Medical AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SEDANA MEDICAL AB",
    "state": null,
    "summary": "Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers AnaConDa and AnaConDa-S, which are disposable medical devices that enables the administration of volatile anesthetics; AnaConDa Syringe, a 50/60ml syringe; FlurAbsorb, a charcoal filter for removing halogenated hydrocarbon anesthetic gases, such as isoflurane or sevoflurane; FlurAbsorb-S, a filter containing activated carbon for the removal of waste anaesthetic gases; FlurAbsorb accessory kit comprising lines and connectors for connecting the filter to the ventilator and gas monitor; and FlurAbsorb and FlurAbsorb-S mount to hold the filter during scavenging of anesthetic gas. It also provides gas sampling lines to prevent anaesthetic volatile agents from leaching through the wall of the tube; and Nafion lines to reduce the accumulation of condensate in the anaesthetic gas measuring line and the water trap of the gas monitor. Sedana Medical AB (publ) was founded in 2005 and is headquartered in Danderyd, Sweden.",
    "website": "http://www.sedanamedical.com",
    "zipcode": "182 32"
  },
  "7IZ.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Ziccum AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZICCUM AB",
    "state": null,
    "summary": "Ziccum AB (publ) develops dry powder preparations of biological pharmaceuticals. The company develops and commercializes LaminarPace, a spray drying technology that dries chemicals, vaccines, biologics, and drug substances at room temperature. Its dry powder biologics includes proteins, antibodies, vaccine viruses, and other products. The company was founded in 2017 and is headquartered in Lund, Sweden.",
    "website": "http://www.ziccum.com",
    "zipcode": "223 70"
  },
  "7PL.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "ProstaLund AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PROSTALUND AB",
    "state": null,
    "summary": "ProstaLund AB (publ) develops and sells urological devices for the treatment of patients with benign prostatic hyperplasia (BPH) in Sweden and internationally. The company also offers CoreTherm, a heat treatment of BPH; and Gepan instill for the treatment of chronic bladder inflammation. Its products are used in hospitals and clinics. The company was founded in 1991 and is based in Lund, Sweden. ProstaLund AB (publ) is a subsidiary of Farstorps Gard Forvaltnings AB.",
    "website": "http://www.prostalund.se",
    "zipcode": "223 62"
  },
  "7UX.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Spago Nanomedical AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SPAGO NANOMEDICAL AB",
    "state": null,
    "summary": "Spago Nanomedical AB (publ) develops nanomaterials for cancer diagnostics and treatment. It offers SpagoPix, a cancer selective MRI contrast agent; and Tumorad, a tumor selective radiation treatment. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was founded in 2007 and is based in Lund, Sweden.",
    "website": "http://spagonanomedical.se",
    "zipcode": "223 63"
  },
  "7V3.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Cantargia AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CANTARGIA AB",
    "state": null,
    "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx antibodies against IL1RAP that have other properties than CAN04 and CAN10. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.",
    "website": "http://cantargia.com",
    "zipcode": "223 63"
  },
  "7Z60.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Coegin Pharma AS",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "COEGIN PHARMA AB",
    "state": null,
    "summary": "Coegin Pharma AS, a clinical-stage pharmaceutical company, engages in the discovery and development of novel small molecule therapeutics for the treatment of serious medical conditions associated with chronic inflammatory disorders and specific cancers. Its lead compound AVX001 is a therapy for the treatment of psoriasis and other skin conditions. The company's other products include AVX002 for the treatment of chronic kidney disease (glomerulonephritis); AVX235 for the treatment of triple-negative breast cancer; and AVX420 for the treatment of cancer. Coegin Pharma AS was founded in 2005 and is based in Lund, Sweden. Coegin Pharma AS operates as a subsidiary of Coegin Pharma AB.",
    "website": "http://coeginpharma.com",
    "zipcode": "223 81"
  },
  "80R.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "AroCell AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AROCELL AB",
    "state": null,
    "summary": "AroCell AB (publ), a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company offers TK 210 ELISA, a kit for the determination of Thymidine Kinase 1 in human blood. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was founded in 2003 and is based in Uppsala, Sweden.",
    "website": "http://www.arocell.com",
    "zipcode": "754 50"
  },
  "8LY.F": {
    "city": "Bromma",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "OncoZenge AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ONCOZENGE AB",
    "state": null,
    "summary": "OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).",
    "website": "http://www.oncozenge.se",
    "zipcode": "167 51"
  },
  "8T0.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Promore Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PROMORE PHARMA AK",
    "state": null,
    "summary": "Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand, which is in Phase III trial; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers and for the treatment of diabetic foot ulcers. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is based in Solna, Sweden.",
    "website": "http://www.promorepharma.com",
    "zipcode": "171 65"
  },
  "8V6.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Scandinavian ChemoTech AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SCANDINAV.CHEMOTECH CL.B",
    "state": null,
    "summary": "Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.",
    "website": "http://chemotech.se",
    "zipcode": "223 63"
  },
  "8X4.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Eurocine Vaccines AB (publ)",
    "market": "dr_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "EUROCINE VACCINES NAM.",
    "state": null,
    "summary": "Eurocine Vaccines AB (publ) develops vaccines in Sweden. It has a research and collaboration agreement with Spixia Biotechnology AB to develop, manufacture, and commercialize chlamydia vaccine candidates. The company is based in Solna, Sweden.",
    "website": "http://www.eurocine-vaccines.com",
    "zipcode": "171 65"
  },
  "9480.F": {
    "city": "LinkÃ¶ping",
    "country": "Sweden",
    "currency": null,
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "SyntheticMR AB (publ)",
    "market": "dr_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": null,
    "state": null,
    "summary": "SyntheticMR AB (publ) develops and markets software solutions for magnetic resonance imaging (MRI) in Sweden and internationally. The company's SyMRI delivers various contrast images, biomarker segmentations, and quantitative data with a single MR sequence. It offers SyMRI NEURO delivers multiple contrast images, tissue segmentations, and quantitative data on the brain, as well as objective decision support; SyMRI MSK provides multiple contrast images and quantitative data for MSK anatomies; and MAGiC, a customized version of SyMRI. The company was founded in 2007 and is headquartered in LinkÃ¶ping, Sweden.",
    "website": "http://www.syntheticmr.com",
    "zipcode": "582 23"
  },
  "958.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Pharmiva AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMIVA AB",
    "state": null,
    "summary": "Pharmiva AB (publ) engages in the research and development of medical products. The company develops Vernivia, an over-the-counter vaginal mousse for the treatment of bacterial vaginosis. The company is based in Lund, Sweden.",
    "website": "http://www.pharmiva.com",
    "zipcode": "22270"
  },
  "99B.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "QUIAPEG PHARMAC.H.SK-1,20",
    "state": null,
    "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.",
    "website": "http://www.quiapeg.com",
    "zipcode": "171 65"
  },
  "9IB.SG": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Infant Bacterial Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Infant Bacterial Therapeutics N",
    "state": null,
    "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.",
    "website": "http://www.ibtherapeutics.com",
    "zipcode": "111 21"
  },
  "9II.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Biovica International AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIOVICA INTERNATIONAL",
    "state": null,
    "summary": "Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome in Europe, the United States, and Asia. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves pharmaceutical companies and contract research organizations. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.biovica.com",
    "zipcode": "752 37"
  },
  "9RP.F": {
    "city": "UmeÃ¥",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Lipigon Pharmaceuticals AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIPIGON PHARMA. AB",
    "state": null,
    "summary": "Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) was founded in 2010 and is based in UmeÃ¥, Sweden.",
    "website": "http://www.lipigon.se",
    "zipcode": "90736"
  },
  "A39.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Distribution",
    "long_name": "Arjo AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ARJO AB B",
    "state": null,
    "summary": "Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The company offers products and solutions for patient handling, hygiene, disinfection, medical beds, treatment and prevention of pressure injuries and leg ulcers, prevention of deep vein thrombosis, treatment of edema, and for obstetric and cardiac diagnostics. It also provides dementia and bariatric room assessment solutions, as well as clinical consulting, maintenance, and equipment rental and financing solutions. The company serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.arjo.com",
    "zipcode": "211 20"
  },
  "A6X.F": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "aXichem AB",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "AXICHEM AB A",
    "state": null,
    "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in MalmÃ¶, Sweden.",
    "website": "http://www.axichem.com",
    "zipcode": "211 34"
  },
  "ABLI.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Abliva AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Abliva AB",
    "state": null,
    "summary": "Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://abliva.com",
    "zipcode": "223 81"
  },
  "AC6.F": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AlzeCure Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALZECURE PHARMA AB",
    "state": null,
    "summary": "AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of diseases and conditions that affect the central nervous system. The company is developing five drug candidates based on the NeuroRestore and Alzstatin research platforms. Its pipeline drug candidates include ACD855, which is in Phase I clinical trial for sleep disruptions, traumatic brain injuries, and Alzheimer's disease; ACD856, ACD679, and ACD680 for Alzheimer's disease; ACD857 for eye/ear indications; VR1 that is in Phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.",
    "website": "http://www.alzecurepharma.se",
    "zipcode": "141 57"
  },
  "ACARIX.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Acarix AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Acarix AB",
    "state": null,
    "summary": "Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases. The company offers CADScor System for the diagnosis of coronary artery disease. It operates in Germany, Sweden, Denmark, and internationally. Acarix AB (publ) was founded in 2009 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.acarix.com",
    "zipcode": "211 19"
  },
  "ACE.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Ascelia Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Ascelia Pharma AB",
    "state": null,
    "summary": "Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. The company was founded in 2000 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.ascelia.com",
    "zipcode": "215 32"
  },
  "ACOU.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "AcouSort AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AcouSort AB",
    "state": null,
    "summary": "AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.",
    "website": "http://www.acousort.com",
    "zipcode": "223 81"
  },
  "ACTI.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Active Biotech AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Active Biotech AB",
    "state": null,
    "summary": "Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. The company is developing Naptumomab, an anti-cancer immunotherapy that is in Phase Ib/II clinical trial to treat patients with advanced solid tumors; and Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. It is also developing Laquinimod, a small molecule immuno-modulator to treat inflammatory eye disorders, non-infectious uveitis, and wet age-related macular degeneration (wAMD). The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.",
    "website": "http://www.activebiotech.com",
    "zipcode": "223 63"
  },
  "ADDERA.ST": {
    "city": "Helsingborg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Care Facilities",
    "long_name": "AdderaCare AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AdderaCare AB",
    "state": null,
    "summary": "AdderaCare AB, through its subsidiaries, operates in the home care sector. The company offers ramps for housing adaptations; stairs and lifts, and bathroom equipment for people with functional limitations; mobility aids for people with special needs; sensory stimulation aids; sensory rooms; sensory furniture; vestibular products; motor training products; orthopaedic shoes; orthoses; and prosthesis and components for prosthesis. It also provides construction brackets; products for gross and fine motor functions; orthotics; orthopaedic aids; three-wheel bikes; supervised cycling bikes; mobility scooters; and wheelchair scooters. The company primarily serves municipalities, county councils, and private individuals. The company was formerly known as Mastaban AB and changed its name to AdderaCare AB in 2016. AdderaCare AB was founded in 2013 and is based in Helsingborg, Sweden.",
    "website": "http://www.adderacare.com",
    "zipcode": "252 20"
  },
  "ADDV-A.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "ADDvise Group AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ADDvise Group AB A",
    "state": null,
    "summary": "ADDvise Group AB (publ) develops and supplies equipment and services to healthcare and research facilities in private and public sectors in Sweden, rest of Europe, North America, and Asia. The company's Lab business unit offers laboratory furnishings, safety ventilation products, climate rooms, clean rooms, and laboratory apparatus. Its Healthcare business unit develops, manufactures, and markets vacuum mattresses, pillows and splints, and vacuum products, as well as equipment for pilots, such as flight suits and Anti-G suits; healthcare equipment, such as bags and carrying systems, as well as equipment and consumable materials, such as intra-osseous and biopsy needles; equipment for patient positioning, primarily within urology and gynecology areas; and surgical tables for medical care. The company was formerly known as ADDvise Lab Solutions AB (publ) and changed its name to ADDvise Group AB (publ) in September 2015. ADDvise Group AB (publ) was founded in 1989 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.addvisegroup.se",
    "zipcode": "114 46"
  },
  "ADDV-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "ADDvise Group AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ADDvise Group AB B",
    "state": null,
    "summary": "ADDvise Group AB (publ) develops and supplies equipment and services to healthcare and research facilities in private and public sectors in Sweden, rest of Europe, North America, and Asia. The company's Lab business unit offers laboratory furnishings, safety ventilation products, climate rooms, clean rooms, and laboratory apparatus. Its Healthcare business unit develops, manufactures, and markets vacuum mattresses, pillows and splints, and vacuum products, as well as equipment for pilots, such as flight suits and Anti-G suits; healthcare equipment, such as bags and carrying systems, as well as equipment and consumable materials, such as intra-osseous and biopsy needles; equipment for patient positioning, primarily within urology and gynecology areas; and surgical tables for medical care. The company was formerly known as ADDvise Lab Solutions AB (publ) and changed its name to ADDvise Group AB (publ) in September 2015. ADDvise Group AB (publ) was founded in 1989 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.addvisegroup.se",
    "zipcode": "114 46"
  },
  "AEGIR.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "AegirBio AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "AegirBio AB",
    "state": null,
    "summary": "Aegirbio AB, a diagnostic company, offers tests to monitor and optimize the dosage of biological drugs in Sweden. The company focuses on therapeutic drug monitoring of biologic therapies in the autoimmune, oncology, and neurology space. It offers moNATor, a first dose-monitoring laboratory test to multiple sclerosis for healthcare professionals and patients. The company is based in Lund, Sweden.",
    "website": "http://aegirbio.com",
    "zipcode": "223 70"
  },
  "AINO.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Health Information Services",
    "long_name": "Aino Health AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Aino Health AB",
    "state": null,
    "summary": "Aino Health AB (publ) provides corporate health management solutions for private and public organizations in Finland. It offers HealthManager, a software as a service solution that provides surveys, analytics, exposure checks, and security and GDPR services; and e-learning platform. The company also provides telemedicine services; professional services, including analytics, management and employee support, and well-being services; onboarding services, such as project management and planning, implementation, and training and communication services; and other services to occupational health care providers, insurance companies, IT software and service companies, HR, payroll service centers, nurses, online therapists, etc. Aino Health AB (publ) is based in Stockholm, Sweden.",
    "website": "http://www.ainohealth.com",
    "zipcode": "115 23"
  },
  "ALIF-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "AddLife AB (publ)",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "AddLife AB ser. B",
    "state": null,
    "summary": "AddLife AB (publ), together with its subsidiaries, supplies equipment, instruments, and reagents to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries in Sweden, Finland, Denmark, Norway, and internationally. The company operates through two segments, Labtech and Medtech. The Labtech segment provides analysis instruments, equipment, microscopes, consumables and reagents, as well as software support and technical services primarily to laboratories in medicine, research, academia, food, pharmaceutical, microbiology, clinical chemistry, coagulation, molecular biology, immunology, point-of-care testing, and veterinary diagnostics industries. This segment also offers training programs, seminars, and advisory services. The Medtech segment provides medical device products to surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ear, nose and throat, ostomies, and home healthcare markets. AddLife AB (publ) was founded in 1906 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.add.life",
    "zipcode": "103 62"
  },
  "ALZ.ST": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Alzinova AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Alzinova AB",
    "state": null,
    "summary": "Alzinova AB, a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic AÃ oligomers. The company was founded in 2011 and is based in MÃ¶lndal, Sweden.",
    "website": "http://www.alzinova.com",
    "zipcode": "431 83"
  },
  "ALZCUR.ST": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AlzeCure Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AlzeCure Pharma AB",
    "state": null,
    "summary": "AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of diseases and conditions that affect the central nervous system. The company is developing five drug candidates based on the NeuroRestore and Alzstatin research platforms. Its pipeline drug candidates include ACD855, which is in Phase I clinical trial for sleep disruptions, traumatic brain injuries, and Alzheimer's disease; ACD856, ACD679, and ACD680 for Alzheimer's disease; ACD857 for eye/ear indications; VR1 that is in Phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.",
    "website": "http://www.alzecurepharma.se",
    "zipcode": "141 57"
  },
  "AMBEA.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Care Facilities",
    "long_name": "Ambea AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Ambea AB",
    "state": null,
    "summary": "Ambea AB (publ) provides residential care services for people with special needs in Sweden, Norway, and Denmark. The company operates through five segments: Vardaga, Nytida, Stendi, Altiden, and Klara. It offers permanent residential placements, short-term placements, relief care, and respite care services; home care services, including cleaning, washing, shopping, private nursing, cooking, walks, and companionship; child care homes, holiday camps, and short-term housing services; group homes, assisted living facilities, and day services; and support services, such as homes for care or residence, assisted living facilities, supported living facilities, foster homes, sheltered housing, non-residential care and assessments for children, young people, and adults. The company also provides day-care centers, elementary schools, special needs elementary schools, and special needs upper secondary schools for children and young people with neuropsychiatric disabilities; residential and care services for adults with disabilities, abuse problems, early-onset dementia, and mental health problems; short-break residential facilities for children and young people with disabilities; user-controlled personal assistance for children and adults; senior apartments, nursing homes, day centers, home care, and rehabilitation services for elderly people. In addition, it offers ambulatory care, emergency care team, and rehabilitation staff services; supplies temporary doctors, nurses, psychologists, and speech pathologists; and recruitment services for nurses and unit managers. Ambea AB (publ) was founded in 1996 and is headquartered in Solna, Sweden.",
    "website": "http://www.ambea.se",
    "zipcode": "171 29"
  },
  "ANNX.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Annexin Pharmaceuticals AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Annexin Pharmaceuticals AB",
    "state": null,
    "summary": "Annexin Pharmaceuticals AB (publ), a biotechnology company, engages in developing drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.",
    "website": "http://www.annexinpharma.com/sv",
    "zipcode": "113 29"
  },
  "ARCOMA.ST": {
    "city": "VÃ¤xjÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Arcoma AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Arcoma AB",
    "state": null,
    "summary": "Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. The company sells its products through OEM partners. Arcoma AB was founded in 1990 and is based in VÃ¤xjÃ¶, Sweden.",
    "website": "http://www.arcoma.se",
    "zipcode": "352 46"
  },
  "ARJO-B.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Distribution",
    "long_name": "Arjo AB (publ)",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Arjo AB ser. B",
    "state": null,
    "summary": "Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The company offers products and solutions for patient handling, hygiene, disinfection, medical beds, treatment and prevention of pressure injuries and leg ulcers, prevention of deep vein thrombosis, treatment of edema, and for obstetric and cardiac diagnostics. It also provides dementia and bariatric room assessment solutions, as well as clinical consulting, maintenance, and equipment rental and financing solutions. The company serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.arjo.com",
    "zipcode": "211 20"
  },
  "AROC.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Diagnostics & Research",
    "long_name": "AroCell AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AroCell AB (publ)",
    "state": null,
    "summary": "AroCell AB (publ), a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company offers TK 210 ELISA, a kit for the determination of Thymidine Kinase 1 in human blood. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was founded in 2003 and is based in Uppsala, Sweden.",
    "website": "http://www.arocell.com",
    "zipcode": "754 50"
  },
  "ASAP.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Asarina Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Asarina Pharma AB",
    "state": null,
    "summary": "Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder, as well as in Phase IIa clinical trial for the treatment of menstrual migraine and Tourette syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.",
    "website": "http://www.asarinapharma.com",
    "zipcode": "171 65"
  },
  "ATORX.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Alligator Bioscience AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Alligator Bioscience AB",
    "state": null,
    "summary": "Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in the United States, Sweden, Asia, and internationally. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial to treat metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://www.alligatorbioscience.se",
    "zipcode": "223 81"
  },
  "ATT.ST": {
    "city": "Danderyd",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Care Facilities",
    "long_name": "Attendo AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Attendo AB",
    "state": null,
    "summary": "Attendo AB (publ) provides financed care services in Sweden, Finland, Norway, and Denmark. The company offers care services for older people in nursing homes and home care. It also provides disabilities care services for people with disabilities, such as homes and supportive housing, daily activities, respite care, and short-term accommodation; and social psychiatry, and emergency shelters and family support homes for individuals and family. The company also operates group homes for adults, homes for children with special needs; consultant supported family home care services; crisis and acute accommodations; and substance abuse care services. It also offers home care services based on outsourcing contracts. Attendo AB (publ) was founded in 1985 and is headquartered in Danderyd, Sweden.",
    "website": "http://www.attendo.com",
    "zipcode": "182 91"
  },
  "AXIC-A.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "aXichem AB",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "aXichem AB ser. A",
    "state": null,
    "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in MalmÃ¶, Sweden.",
    "website": "http://www.axichem.com",
    "zipcode": "211 34"
  },
  "B6E.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Swedish Orphan Biovitrum AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SWEDISH ORPHAN BIOVIT.SK1",
    "state": null,
    "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.",
    "website": "http://www.sobi.com",
    "zipcode": "112 76"
  },
  "B9A.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BioArctic AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOARCTIC AB B",
    "state": null,
    "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.",
    "website": "http://www.bioarctic.se",
    "zipcode": "112 51"
  },
  "BACTI-B.ST": {
    "city": "Tullinge",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Bactiguard Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Bactiguard Holding AB ser. B",
    "state": null,
    "summary": "Bactiguard Holding AB (publ), a medical device company, engages in the research and development, production, marketing, and sale of infection prevention solutions. Its infection prevention solutions prevent healthcare associated infections caused by medical devices. The company's products portfolio reduces the risk of infections in the urinary tract, the respiratory tract, and the bloodstream. Its product portfolio consists of Bactiguard infection protection (BIP) Foley Catheter, an indwelling urinary catheter that reduces microbial adhesion; BIP Central Venous Catheter, which reduces the risk of biofilm formation and infection; BIP Endotracheal Tube that reduces the risk of infection; BIP Endotracheal Tube Evac, which is used to reduce microbial adhesion; and BIP Foley TempSensor, an indwelling urinary catheter that combines surveillance and infection prevention. The company's products also include Hydrocyn aqua advanced wound care, a wound wash, debridement, and irrigation solution for chronic and acute wounds; surgical sutures comprise of non-absorbable, natural absorbable, synthetic absorbable, and specialty sutures; VigiMesh, a sterile, non-absorbable, and knitted polypropylene monofilament mesh material for tissue reinforcement for use in hernia repair; and Hydrocyn aqua advanced disinfectant, a non-alcoholic disinfectant for skin and surfaces to kill bacteria, virus, and fungi. The company serves in the United States, Sweden, Malaysia, China, Thailand, Bangladesh, New Zealand, and internationally. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.",
    "website": "http://www.bactiguard.com",
    "zipcode": "146 21"
  },
  "BGAIF": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "BioGaia AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOGAIA AG",
    "state": null,
    "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pyloriÂthe gastric ulcer bacterium; and low bone density. The company offers its products under the brand name of BioGaia. The company was founded in 1990 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.biogaia.com",
    "zipcode": "112 27"
  },
  "BGL.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "BioGaia AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOGAIA AB  B  SK 1",
    "state": null,
    "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pyloriÂthe gastric ulcer bacterium; and low bone density. The company offers its products under the brand name of BioGaia. The company was founded in 1990 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.biogaia.com",
    "zipcode": "112 27"
  },
  "BINV.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "BioInvent International AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BioInvent International AB",
    "state": null,
    "summary": "BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, rest of Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia. The company is also developing cancer-associated regulatory T cells which modulate the immune system; and BI-1808 and BI-1910, an anti-TNFR2 antibody for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors; and a collaboration agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was incorporated in 1996 and is headquartered in Lund, Sweden.",
    "website": "http://www.bioinvent.com",
    "zipcode": "223 70"
  },
  "BIOA-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "BioArctic AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BioArctic AB ser. B",
    "state": null,
    "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.",
    "website": "http://www.bioarctic.se",
    "zipcode": "112 51"
  },
  "BIOG-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "BioGaia AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BioGaia AB ser. B",
    "state": null,
    "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pyloriÂthe gastric ulcer bacterium; and low bone density. The company offers its products under the brand name of BioGaia. The company was founded in 1990 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.biogaia.com",
    "zipcode": "112 27"
  },
  "BIOGY": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "BioGaia AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOGAIA AG",
    "state": null,
    "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic and digestive health in children; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; general health; Helicobacter pyloriÂthe gastric ulcer bacterium; and low bone density. The company offers its products under the brand name of BioGaia. The company was founded in 1990 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.biogaia.com",
    "zipcode": "112 27"
  },
  "BIOS.ST": {
    "city": "Kista",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Bioservo Technologies AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Bioservo Technologies AB",
    "state": null,
    "summary": "Bioservo Technologies AB (publ) develops wearable muscle strengthening systems worldwide. It offers Ironhand, a robotic muscle strengthening system for professional applications; and Carbonhand, a grip enhancing device that facilitates a normal movement pattern for use in healthcare applications. Bioservo Technologies AB (publ) was founded in 2006 and is based in Kista, Sweden.",
    "website": "http://www.bioservo.com",
    "zipcode": "164 40"
  },
  "BIOT.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Biotage AB",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Biotage AB",
    "state": null,
    "summary": "Biotage AB (publ), a life science company, provides separation technologies in the areas of organic and analytical chemistry, biomolecules, as well as for industrial scale up applications. It offers sample preparation solutions; horizon food and environmental products; microwave synthesis solutions; peptide synthesis and purification solutions; flash purification products; work-up products; evaporation and concentration solutions; and industrial and large scale products, such as flash purification, metal scavenging, reagents and scavengers, and custom resins. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, government authorities, and academic institutions; and commercial labs, hospital, CROs, bio-analytical laboratories, food manufacturers, and labs performing for food safety and environmental analysis. It operates in North and South America, Europe, Japan, China, South Korea, India, the Middle East, Africa, and Asia Pacific. The company was founded in 1969 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.biotage.com",
    "zipcode": "751 03"
  },
  "BIOVF": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Swedish Orphan Biovitrum AB (publ)",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SWEDISH ORPHAN BIOVITRUM AB",
    "state": null,
    "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.",
    "website": "http://www.sobi.com",
    "zipcode": "112 76"
  },
  "BIOVIC-B.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Biovica International AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Biovica International AB ser. B",
    "state": null,
    "summary": "Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome in Europe, the United States, and Asia. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves pharmaceutical companies and contract research organizations. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.biovica.com",
    "zipcode": "752 37"
  },
  "BIOWKS.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Bio-Works Technologies AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Bio-Works Technologies AB",
    "state": null,
    "summary": "Bio-Works Technologies AB (publ) researches, develops, manufactures, and supplies agarose based resins used to separate proteins and other biomolecules. It offers activated and affinity resins; BabyBio columns; immobilized metal-ion affinity chromatography (IMAC) resins; ion exchange resins; OptioBio glass columns; and size exclusion chromatography (SEC) resins. The company's products are used in antibody, His-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines purification process. Bio-Works Technologies AB (publ) founded in 2006 and is based in Uppsala, Sweden.",
    "website": "http://www.bio-works.com",
    "zipcode": "75450"
  },
  "BIX0.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "BioInvent International AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOINVENT INTERN.  SK 2",
    "state": null,
    "summary": "BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, rest of Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia. The company is also developing cancer-associated regulatory T cells which modulate the immune system; and BI-1808 and BI-1910, an anti-TNFR2 antibody for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors; and a collaboration agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was incorporated in 1996 and is headquartered in Lund, Sweden.",
    "website": "http://www.bioinvent.com",
    "zipcode": "223 70"
  },
  "BONEX.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Bonesupport Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BONESUPPORT HOLDING AB",
    "state": null,
    "summary": "Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes for the treatment of bone disorders in Sweden, rest of Europe, North America, and internationally. The company offers CERAMENT Bone Void Filler, a resorbable ceramic bone graft substitute used to fill gaps and voids in the skeletal system to promote bone healing; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It is also developing preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. The company's products are used in orthopedic markets. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.",
    "website": "http://www.bonesupport.com",
    "zipcode": "223 70"
  },
  "BOUL.ST": {
    "city": "SpÃ¥nga",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Diagnostics & Research",
    "long_name": "Boule Diagnostics AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Boule Diagnostics AB",
    "state": null,
    "summary": "Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. It provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning kits and plastic micro capillaries under the Swelab, Medonic, and Quintus brands; and veterinary clinical chemistry analyzer and diagnostics systems under the Exigo brand. The company sells its products directly in Sweden and the United States, as well as through distributors internationally. It serves hospitals, clinics, laboratories, healthcare centers and veterinary clinics, and companies in blood diagnostics. The company has operations in Sweden, the United States, Mexico, and Russia. Boule Diagnostics AB (publ) was founded in 1956 and is headquartered in SpÃ¥nga, Sweden.",
    "website": "http://www.boule.com",
    "zipcode": "163 53"
  },
  "BRIG.ST": {
    "city": "Kista",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Brighter AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Brighter AB",
    "state": null,
    "summary": "Brighter AB (publ), a health-tech company, develops data-driven solutions for the treatment of chronic condition in Sweden. It is developing Actiste, a mobile-connected device to remotely monitor and treat insulin-dependent diabetes; and The Benefit Loop, a cloud-based platform that gathers, processes, analyzes, and organizes real-life data. The company offers its products to consumers and patients, mobile network operators, healthcare providers, governments/authorities, insurance companies, consumers, companies/employers, clinical research organizations, pharmaceutical companies, research and development organizations, authorities, and academic bodies. Brighter AB (publ) was founded in 2007 and is based in Kista, Sweden.",
    "website": "http://brighter.se",
    "zipcode": "164 32"
  },
  "BTPC.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Active Biotech AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACTIVE BIOTECH  SK 10",
    "state": null,
    "summary": "Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. The company is developing Naptumomab, an anti-cancer immunotherapy that is in Phase Ib/II clinical trial to treat patients with advanced solid tumors; and Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. It is also developing Laquinimod, a small molecule immuno-modulator to treat inflammatory eye disorders, non-infectious uveitis, and wet age-related macular degeneration (wAMD). The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.",
    "website": "http://www.activebiotech.com",
    "zipcode": "223 63"
  },
  "C26.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "CellaVision AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CELLAVISION AB  SK -,15",
    "state": null,
    "summary": "CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. It offers reagents, analyzers, supplementary software, and peripheral equipment for digital microscopy in the field of hematology. The company also provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. In addition, it offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. Further, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.",
    "website": "http://www.cellavision.com",
    "zipcode": "223 62"
  },
  "C5G.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Orexo AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OREXO AB  SK-,40",
    "state": null,
    "summary": "Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.orexo.com",
    "zipcode": "754 50"
  },
  "CALT": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Calliditas Therapeutics AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Calliditas Therapeutics AB",
    "state": null,
    "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.calliditas.se",
    "zipcode": "111 22"
  },
  "CALTX.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Calliditas Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Calliditas Therapeutics AB",
    "state": null,
    "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a novel oral formulation of budesonide potent local immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.calliditas.se",
    "zipcode": "111 22"
  },
  "CAMX.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Camurus AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Camurus AB",
    "state": null,
    "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; and episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity. Its products pipeline also includes Brixadi for opioid dependence; CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension and Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4083 for treatment of myasthenia gravis and other serious tissue-based complement-mediated disorders; CAM2047 for the treatment of chemotherapy induced nausea and vomiting; and CAM2048 for postoperative pain. The company was founded in 1991 and is headquartered in Lund, Sweden.",
    "website": "http://www.camurus.com",
    "zipcode": "223 70"
  },
  "CANTA.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Cantargia AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Cantargia AB",
    "state": null,
    "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It is also developing CANxx antibodies against IL1RAP that have other properties than CAN04 and CAN10. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.",
    "website": "http://cantargia.com",
    "zipcode": "223 63"
  },
  "CEVI.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "CellaVision AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CellaVision AB",
    "state": null,
    "summary": "CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. It offers reagents, analyzers, supplementary software, and peripheral equipment for digital microscopy in the field of hematology. The company also provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. In addition, it offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. Further, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.",
    "website": "http://www.cellavision.com",
    "zipcode": "223 62"
  },
  "CLBIO.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Corline Biomedical AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Corline Biomedical AB",
    "state": null,
    "summary": "Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.",
    "website": "http://www.corline.se",
    "zipcode": "754 50"
  },
  "CLLKF": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Cellink AB (publ)",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "CELLINK AB",
    "state": null,
    "summary": "Cellink AB (publ), a bio convergence company, designs and develops bioprinting, liquid handling, single-cell analysis, and live-cell imaging technologies in North America, Europe, Asia, and internationally. The company's bioprinting solutions include BIO MDX, bioprinting systems for biomedical manufacturing; BIO X, 3D bioprinter for cell biologists, tissue engineers and biomedical researchers; BIO X6, a 6 printhead 3D bioprinter; INKREDIBLE and INKREDIBLE+, which are 3D bioprinting solutions; Holograph X, provides ultra-high-resolution 3D bioprinting at the micrometer level using holographic stereolithography; and Lumen X, a solution that offers applications in microfluidics, cell-laden hydrogels, macroporous structures. It also offers C.BIRD, a microbioreactor for cell line development, as well as SOLARIS BIOREACTORS, a platforms for research and development, and product development applications; UP.SIGHT, a cell line development solution; Single-Cell Printer, an automated laboratory instrument; C.SIGHT, a single-cell dispensing technology for cell line development and single-cell genomics; B.SIGHT, a solution that enables prokaryotic cell isolation in the sub-micron range; and F.SIGHT, a solution that dispenses unlabeled and fluorescent cells. In addition, the company provides I-DOT, a solution for liquid-handling tasks; C.WASH, a plate washer; LIVECYTE, a kinetic cytometer; CELLCYTE X, a live cell imaging system; and CASY, a cell status monitoring solution, as well as open qPCR system and NGS reagents. Further, it offers consumables, and hand sanitizers and sanitizing wipes. The company serves universities, research organizations, pharmaceutical companies, and cosmetic and skin care companies, as well as packaging and automotive industries. It has strategic partnership with Made In Space for advancing bioprinting technology in space. The company also offers products online. Cellink AB (publ) was founded in 2016 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.cellink.com",
    "zipcode": "413 46"
  },
  "CLNK-B.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Cellink AB (publ)",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "CELLINK AB ser. B",
    "state": null,
    "summary": "Cellink AB (publ), a bio convergence company, designs and develops bioprinting, liquid handling, single-cell analysis, and live-cell imaging technologies in North America, Europe, Asia, and internationally. The company's bioprinting solutions include BIO MDX, bioprinting systems for biomedical manufacturing; BIO X, 3D bioprinter for cell biologists, tissue engineers and biomedical researchers; BIO X6, a 6 printhead 3D bioprinter; INKREDIBLE and INKREDIBLE+, which are 3D bioprinting solutions; Holograph X, provides ultra-high-resolution 3D bioprinting at the micrometer level using holographic stereolithography; and Lumen X, a solution that offers applications in microfluidics, cell-laden hydrogels, macroporous structures. It also offers C.BIRD, a microbioreactor for cell line development, as well as SOLARIS BIOREACTORS, a platforms for research and development, and product development applications; UP.SIGHT, a cell line development solution; Single-Cell Printer, an automated laboratory instrument; C.SIGHT, a single-cell dispensing technology for cell line development and single-cell genomics; B.SIGHT, a solution that enables prokaryotic cell isolation in the sub-micron range; and F.SIGHT, a solution that dispenses unlabeled and fluorescent cells. In addition, the company provides I-DOT, a solution for liquid-handling tasks; C.WASH, a plate washer; LIVECYTE, a kinetic cytometer; CELLCYTE X, a live cell imaging system; and CASY, a cell status monitoring solution, as well as open qPCR system and NGS reagents. Further, it offers consumables, and hand sanitizers and sanitizing wipes. The company serves universities, research organizations, pharmaceutical companies, and cosmetic and skin care companies, as well as packaging and automotive industries. It has strategic partnership with Made In Space for advancing bioprinting technology in space. The company also offers products online. Cellink AB (publ) was founded in 2016 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.cellink.com",
    "zipcode": "413 46"
  },
  "CLS-B.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Clinical Laserthermia Systems AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Clinical Laserthermia Systems A",
    "state": null,
    "summary": "Clinical Laserthermia Systems AB (publ) develops and markets therapies, systems, and single-use instruments for thermal treatment of solid cancer tumors in Sweden. The company offers TRANBERG, a cancer immunotherapy system that includes a laser unit with unique monitoring capabilities and tailored single-use products primarily developed for imILT treatment; and applicator kit. It also is developing products for the treatment of breast, pancreatic, skin, and prostate cancers, as well as other solid cancer tumors. Clinical Laserthermia Systems AB (publ) has a collaboration agreement with Image Guided Therapy SA to develop and commercialize a software product for MR-generated temperature monitoring; collaborative license and co-development agreement with MRI Interventions, Inc. to provide navigation and laser ablation platforms for use in spine and neurosurgery; and clinical trial collaboration with Toronto General Hospital regarding MRI-guided laser ablation treatment of prostate cancer. The company is headquartered in Lund, Sweden.",
    "website": "http://www.clinicallaser.se",
    "zipcode": "223 81"
  },
  "CLTEF": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Calliditas Therapeutics AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CALLIDITAS THERAPEUTICS AB",
    "state": null,
    "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a novel oral formulation of budesonide potent local immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.calliditas.se",
    "zipcode": "111 22"
  },
  "CMOTEC-B.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Scandinavian ChemoTech AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Scandinavian ChemoTech AB B",
    "state": null,
    "summary": "Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.",
    "website": "http://chemotech.se",
    "zipcode": "223 63"
  },
  "COMBI.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "CombiGene AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Combigene AB",
    "state": null,
    "summary": "CombiGene AB (publ) engages in the development and commercialization of gene therapy for the treatment of neurological and psychiatric disorders. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy. CombiGene AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.",
    "website": "http://www.combigene.com",
    "zipcode": "223 81"
  },
  "CONTX.OL": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "NOK",
    "exchange": "OSL",
    "industry": "Health Information Services",
    "long_name": "ContextVision AB (publ)",
    "market": "no_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CONTEXTVISION AB",
    "state": null,
    "summary": "ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers in Asia, Europe, and the United States. It operates in two segments, Business Unit Medical Imaging and Business Unit Digital Pathology. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include US PLUSView, an image enhancement software product for women's health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; GOPiCE, a technology for volumetric image enhancement in real-time; and Rivent that offers unparalleled image quality for various types of ultrasound systems. The company also provides Altumira/Altumira Plus, a solution for various digital radiography systems; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; GOPView Mammo3, an image enhancement software for screening and diagnostic mammography; and INIFY Prostate Screening for digital analysis of prostate biopsies. The company was founded in 1983 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.contextvision.com",
    "zipcode": "111 22"
  },
  "CRAD-B.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "C-Rad AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "C-RAD AB ser. B",
    "state": null,
    "summary": "C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, a real-time tracking solution for particle therapy; Cyrpa laser positioning products; cAccessory, which automates the registration and validation of treatment accessories; and cPatient that automates patient identity validation without the need for contact between patients and devices. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.c-rad.se",
    "zipcode": "753 09"
  },
  "CUR.ST": {
    "city": "Sollentuna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Health Information Services",
    "long_name": "Curando Nordic AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Curando Nordic AB",
    "state": null,
    "summary": "Curando Nordic AB (publ) provides personal care and health services using digital technology in Sweden. It offers services for work environment, as well as solutions for businesses, such as work checklist, E-learning-work environment bas, and education in ergonomics. The company has a strategic cooperation with the Arena Group for services in the areas of health and rehabilitation, crew and recruitment, and career and conversion. The company was formerly known as Rethinking Care Sweden AB (publ) and changed its name to Curando Nordic AB (publ) in June 2018. Curando Nordic AB (publ) was founded in 2016 and is based in Sollentuna, Sweden.",
    "website": "http://www.curando.se",
    "zipcode": "191 61"
  },
  "CYXO.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Cyxone AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Cyxone AB",
    "state": null,
    "summary": "Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis; and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.cyxone.com",
    "zipcode": "221 22"
  },
  "DIGN.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Dignitana AB (publ.)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Dignitana AB",
    "state": null,
    "summary": "Dignitana AB (publ.), a medical technology company, develops, produces, and markets medical cooling devices primarily in the United States. It offers DigniCap, a scalp cooling system used to reduce hair loss from certain chemotherapy treatments, as well as in the treatment of breast cancer. Dignitana AB (publ.) was incorporated in 2007 is headquartered in Lund, Sweden.",
    "website": "http://dignitana.com",
    "zipcode": "226 60"
  },
  "DIZTF": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Dignitana AB (publ.)",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "DIGNITANA AB",
    "state": null,
    "summary": "Dignitana AB (publ.), a medical technology company, develops, produces, and markets medical cooling devices primarily in the United States. It offers DigniCap, a scalp cooling system used to reduce hair loss from certain chemotherapy treatments, as well as in the treatment of breast cancer. Dignitana AB (publ.) was incorporated in 2007 is headquartered in Lund, Sweden.",
    "website": "http://dignitana.com",
    "zipcode": "226 60"
  },
  "DMN.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Diamyd Medical AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "DIAMYD MEDICAL B",
    "state": null,
    "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.",
    "website": "http://www.diamyd.com",
    "zipcode": "111 56"
  },
  "DMYD-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Diamyd Medical AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Diamyd Medical AB ser. B",
    "state": null,
    "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.",
    "website": "http://www.diamyd.com",
    "zipcode": "111 56"
  },
  "DOXA.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Doxa AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Doxa AB",
    "state": null,
    "summary": "Doxa AB (publ), a dental company, develops, manufactures, and commercializes bioceramic dental products under the Ceramir brand worldwide. It offers Crown & Bridge, a dental cement that is used for permanent cementing of crowns and bridges. The company was founded in 1987 and is based in Uppsala, Sweden.",
    "website": "http://www.doxa.se",
    "zipcode": "754 50"
  },
  "EGTX.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Egetis Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Egetis Therapeutics AB",
    "state": null,
    "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was founded in 2006 and is based in Stockholm, Sweden.",
    "website": "http://www.egetis.com",
    "zipcode": "114 46"
  },
  "EI9.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Elos Medtech AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ELOS MED.AB B(FRIA)SK6,25",
    "state": null,
    "summary": "Elos Medtech AB (publ) develops and manufactures medical devices and components for the medical technology industry. The company operates in three segments: Dental, Orthopedics, and Life Science. Its products include implants, screws, plates, instruments, drills, pins and wires, prosthetics, digital dentistry workflow products, disposable plastics, HPLC fittings, and other medical plastic parts, as well as original equipment manufacturing products. The company also provides design and development, regulatory, prototyping, testing, process validation, and supply and inventory management, as well as design for manufacturing and engineering services. It has operations in Sweden, Denmark, China, and the United States. The company was formerly known as Elos AB (publ) and changed its name to Elos Medtech AB (publ) in April 2015. Elos Medtech AB (publ) was founded in 1923 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.elosmedtech.com",
    "zipcode": "411 04"
  },
  "EJXB.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Elekta AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ELEKTA AB  B  SK 2",
    "state": null,
    "summary": "Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.elekta.com",
    "zipcode": "103 93"
  },
  "EKTA-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Elekta AB (publ)",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Elekta AB ser. B",
    "state": null,
    "summary": "Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.elekta.com",
    "zipcode": "103 93"
  },
  "EKTAF": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Elekta AB (publ)",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ELEKTA",
    "state": null,
    "summary": "Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.elekta.com",
    "zipcode": "103 93"
  },
  "EKTAY": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Elekta AB (publ)",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ELEKTA",
    "state": null,
    "summary": "Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.elekta.com",
    "zipcode": "103 93"
  },
  "ELOS-B.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Elos Medtech AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Elos Medtech AB ser. B",
    "state": null,
    "summary": "Elos Medtech AB (publ) develops and manufactures medical devices and components for the medical technology industry. The company operates in three segments: Dental, Orthopedics, and Life Science. Its products include implants, screws, plates, instruments, drills, pins and wires, prosthetics, digital dentistry workflow products, disposable plastics, HPLC fittings, and other medical plastic parts, as well as original equipment manufacturing products. The company also provides design and development, regulatory, prototyping, testing, process validation, and supply and inventory management, as well as design for manufacturing and engineering services. It has operations in Sweden, Denmark, China, and the United States. The company was formerly known as Elos AB (publ) and changed its name to Elos Medtech AB (publ) in April 2015. Elos Medtech AB (publ) was founded in 1923 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.elosmedtech.com",
    "zipcode": "411 04"
  },
  "EN9.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Enzymatica AB",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ENZYMATICA AB",
    "state": null,
    "summary": "Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of illness. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; ViruProtect name in Austria and Belgium; ColdGuard name in South Africa; Zerinol Virus Defense in Italy; and Psysiomer Stop Virus in France. It also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden.",
    "website": "http://www.enzymatica.se",
    "zipcode": "223 70"
  },
  "ENZY.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Enzymatica AB",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Enzymatica AB",
    "state": null,
    "summary": "Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of illness. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; ViruProtect name in Austria and Belgium; ColdGuard name in South Africa; Zerinol Virus Defense in Italy; and Psysiomer Stop Virus in France. It also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden.",
    "website": "http://www.enzymatica.se",
    "zipcode": "223 70"
  },
  "EPIS-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Episurf Medical AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Episurf Medical AB B",
    "state": null,
    "summary": "Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in the Nordic countries, Benelux, Germany, the United Kingdom, and internationally. The company offers Episealer Condyle Solo for the treatment of localized cartilage and underlying bone defects on the femoral condyles of the knee joint; Episealer Trochlea Solo to treat localized cartilage and underlying bone defects in the area behind the patella; and Episealer Femoral Twin for the treatment of elongated localized cartilage and underlying bone defects on the femoral condyles and in the trochlea area of the knee joint. It also provides Episealer Talus for osteochondral lesions of the talar dome of the ankle joint; and Epiguide, a patient-specific drill guide for the treatment of painful joints. In addition, the company offers ÂµiFidelity system, a web-based IT platform for damage assessment, surgical pre-planning, and patient customization of implants and related surgical instruments; and Epioscopy, a damage assessment tool. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.",
    "website": "http://episurf.com",
    "zipcode": "114 49"
  },
  "EPSFF": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Episurf Medical AB (publ)",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EPISURF MEDICAL AB",
    "state": null,
    "summary": "Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in the Nordic countries, Benelux, Germany, the United Kingdom, and internationally. The company offers Episealer Condyle Solo for the treatment of localized cartilage and underlying bone defects on the femoral condyles of the knee joint; Episealer Trochlea Solo to treat localized cartilage and underlying bone defects in the area behind the patella; and Episealer Femoral Twin for the treatment of elongated localized cartilage and underlying bone defects on the femoral condyles and in the trochlea area of the knee joint. It also provides Episealer Talus for osteochondral lesions of the talar dome of the ankle joint; and Epiguide, a patient-specific drill guide for the treatment of painful joints. In addition, the company offers ÂµiFidelity system, a web-based IT platform for damage assessment, surgical pre-planning, and patient customization of implants and related surgical instruments; and Epioscopy, a damage assessment tool. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.",
    "website": "http://episurf.com",
    "zipcode": "114 49"
  },
  "ERMA.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Enorama Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Enorama Pharma AB",
    "state": null,
    "summary": "Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in MalmÃ¶, Sweden.",
    "website": "http://www.enorama.se",
    "zipcode": null
  },
  "FEEL.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Healthcare Plans",
    "long_name": "Feelgood Svenska AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Feelgood Svenska AB",
    "state": null,
    "summary": "Feelgood Svenska AB (publ) provides a range of health services to businesses, organizations, and private individuals in Sweden. The company offers health, exercise, and physiotherapy services. Feelgood Svenska AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.feelgood.se",
    "zipcode": "115 23"
  },
  "FGS.SG": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Healthcare Plans",
    "long_name": "Feelgood Svenska AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Feelgood Svenska AB Namn-Aktier",
    "state": null,
    "summary": "Feelgood Svenska AB (publ) provides a range of health services to businesses, organizations, and private individuals in Sweden. The company offers health, exercise, and physiotherapy services. Feelgood Svenska AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.feelgood.se",
    "zipcode": "115 23"
  },
  "FLUI.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Fluicell AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Fluicell AB",
    "state": null,
    "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.",
    "website": "http://www.fluicell.com",
    "zipcode": "413 46"
  },
  "FRISQ.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Health Information Services",
    "long_name": "FRISQ Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "FRISQ Holding AB",
    "state": null,
    "summary": "FRISQ Holding AB (publ) develops and sells software to the care and healthcare sector. The company offers FRISQ Care, a digital process tool for care providers and patients that facilitates planning, implementation, documentation, and monitoring of healthcare activities, as well as provides patients information on their treatment and care history. The company is based in Stockholm, Sweden.",
    "website": "http://www.frisqholding.se",
    "zipcode": "111 44"
  },
  "GABA.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Gabather AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Gabather AB",
    "state": null,
    "summary": "Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was founded in 2014 and is based in MalmÃ¶, Sweden.",
    "website": "http://www.gabather.com",
    "zipcode": "211 20"
  },
  "GENO.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Genovis AB (publ.)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Genovis AB",
    "state": null,
    "summary": "Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.",
    "website": "http://www.genovis.com",
    "zipcode": "220 07"
  },
  "GETI-B.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Getinge AB",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Getinge AB ser. B",
    "state": null,
    "summary": "Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, and logistic automation solutions; practice-oriented monitoring systems and disposables, vascular and cardiothoracic surgery solutions, anesthesia machines, beating heart surgery solutions, ceiling supply units, connected solutions, and indicators, as well as washer-disinfectors, consumables, and IT-solutions. The company also provides endovascular products; chest drain products; endoscope reprocessing; endoscopic vessel harvesting systems; ventilators; extracorporeal life support or extracorporeal membrane oxygenation products; intra-aortic balloon counter pulsation therapies; operating lights; and modular room systems. In addition, it offers operating tables and accessories; operating room (OR) furniture; OR integration systems; OR management solutions; loading and distribution trolleys; patient flow management and transport solutions; sealing equipment; sterile supply management and traceability solutions; surgical perfusion components; surgical assist systems; and trays and baskets, as well as inspection and packaging and after sales consulting services. Further, the company provides professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.getinge.com",
    "zipcode": "417 56"
  },
  "GHP.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Care Facilities",
    "long_name": "GHP Specialty Care AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GHP Specialty Care AB",
    "state": null,
    "summary": "GHP Specialty Care AB (publ) provides healthcare services in the Nordic region and internationally. The company operates specialist clinics that offer services in various areas, including orthopaedics, spine surgery/spine care, obesity surgery and diabetes care, gastroenterology, urology, general surgery, arrhythmia, sports medicine, neurology, skin, and specialist dentistry. It operates 22 specialty care clinics in the Nordic Region. The company was formerly known as Global Health Partner AB (publ) and changed its name to GHP Specialty Care AB (publ) in May 2015. GHP Specialty Care AB (publ) was founded in 2006 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.ghp.se",
    "zipcode": "411 06"
  },
  "GNGBF": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Getinge AB",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "GETINGE AB",
    "state": null,
    "summary": "Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, and logistic automation solutions; practice-oriented monitoring systems and disposables, vascular and cardiothoracic surgery solutions, anesthesia machines, beating heart surgery solutions, ceiling supply units, connected solutions, and indicators, as well as washer-disinfectors, consumables, and IT-solutions. The company also provides endovascular products; chest drain products; endoscope reprocessing; endoscopic vessel harvesting systems; ventilators; extracorporeal life support or extracorporeal membrane oxygenation products; intra-aortic balloon counter pulsation therapies; operating lights; and modular room systems. In addition, it offers operating tables and accessories; operating room (OR) furniture; OR integration systems; OR management solutions; loading and distribution trolleys; patient flow management and transport solutions; sealing equipment; sterile supply management and traceability solutions; surgical perfusion components; surgical assist systems; and trays and baskets, as well as inspection and packaging and after sales consulting services. Further, the company provides professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.getinge.com",
    "zipcode": "417 56"
  },
  "GNGBY": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Getinge AB",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GETINGE AB",
    "state": null,
    "summary": "Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, and logistic automation solutions; practice-oriented monitoring systems and disposables, vascular and cardiothoracic surgery solutions, anesthesia machines, beating heart surgery solutions, ceiling supply units, connected solutions, and indicators, as well as washer-disinfectors, consumables, and IT-solutions. The company also provides endovascular products; chest drain products; endoscope reprocessing; endoscopic vessel harvesting systems; ventilators; extracorporeal life support or extracorporeal membrane oxygenation products; intra-aortic balloon counter pulsation therapies; operating lights; and modular room systems. In addition, it offers operating tables and accessories; operating room (OR) furniture; OR integration systems; OR management solutions; loading and distribution trolleys; patient flow management and transport solutions; sealing equipment; sterile supply management and traceability solutions; surgical perfusion components; surgical assist systems; and trays and baskets, as well as inspection and packaging and after sales consulting services. Further, the company provides professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.getinge.com",
    "zipcode": "417 56"
  },
  "GPXMED.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "GPX Medical AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GPX Medical AB",
    "state": null,
    "summary": "GPX Medical AB operates as a medical technology company. It offers neonatal intensive care with NEOLA, a medical device that offer continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. NEOLA provide intensive care and healthier lives for preterm born infants. The company was founded in 2016 and headquartered in Lund, Sweden.",
    "website": "http://gasporox.se/medical-diagnostics/",
    "zipcode": "227 30"
  },
  "GTN.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Getinge AB",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "GETINGE AB  B FR. SK-,50",
    "state": null,
    "summary": "Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, and logistic automation solutions; practice-oriented monitoring systems and disposables, vascular and cardiothoracic surgery solutions, anesthesia machines, beating heart surgery solutions, ceiling supply units, connected solutions, and indicators, as well as washer-disinfectors, consumables, and IT-solutions. The company also provides endovascular products; chest drain products; endoscope reprocessing; endoscopic vessel harvesting systems; ventilators; extracorporeal life support or extracorporeal membrane oxygenation products; intra-aortic balloon counter pulsation therapies; operating lights; and modular room systems. In addition, it offers operating tables and accessories; operating room (OR) furniture; OR integration systems; OR management solutions; loading and distribution trolleys; patient flow management and transport solutions; sealing equipment; sterile supply management and traceability solutions; surgical perfusion components; surgical assist systems; and trays and baskets, as well as inspection and packaging and after sales consulting services. Further, the company provides professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.getinge.com",
    "zipcode": "417 56"
  },
  "GUARD.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Guard Therapeutics International AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Guard Therapeutics Internationa",
    "state": null,
    "summary": "Guard Therapeutics International AB (publ) develops and commercializes medical applications for the diagnosis and treatment of pre-eclampsia and kidney damage in Sweden. It offers ROSGard, a drug candidate that is based on alpha-1-microglobulin protein, which protects and repairs damaged kidney tissues. The company has collaboration with Antaros Medical to conduct a study in humans undergoing radiation therapy of neuroendocrine tumors. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) is based in Lund, Sweden.",
    "website": "http://www.guardtherapeutics.com",
    "zipcode": "223 63"
  },
  "HEMC.ST": {
    "city": "Karlstad",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Hemcheck Sweden AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Hemcheck Sweden AB",
    "state": null,
    "summary": "Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. The company develops and commercializes Helge, which detects hemolysis in blood samples at the point of care. It serves emergency departments in the European Union and the United States. The company was founded in 2010 and is based in Karlstad, Sweden.",
    "website": "http://www.hemcheck.com",
    "zipcode": "651 88"
  },
  "HNSA.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Hansa Biopharma AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Hansa Biopharma AB",
    "state": null,
    "summary": "Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme that is in Phase II for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain BarrÃ© syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.",
    "website": "http://www.hansabiopharma.com",
    "zipcode": "222 63"
  },
  "HUM.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Care Facilities",
    "long_name": "Humana AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Humana AB",
    "state": null,
    "summary": "Humana AB (publ) provides individual and family care services for children, adolescents, and adults in Sweden, Finland, Norway, and Denmark. The company operates through Individual & Family, Personal Assistance, and Elderly Care segments. The Individual & Family segment provides care and treatment in psychiatry and psychosocial change management through residential care homes, temporary and regular family homes, special service housing, outpatient care and assisted living homes, and specially adapted housing. The Personal Assistance segment offers care services and assistance to individuals with functional impairments. The Elderly Care segment consists of elderly housing, as well as provides day care, flats adapted for the elderly, meeting places, and family member services. Humana AB (publ) was founded in 2001 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.humana.se",
    "zipcode": "112 51"
  },
  "IBT-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Infant Bacterial Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Infant Bacterial Therapeutics A",
    "state": null,
    "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.",
    "website": "http://www.ibtherapeutics.com",
    "zipcode": "111 21"
  },
  "ICO.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Iconovo AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Iconovo AB",
    "state": null,
    "summary": "Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a reservoir-based dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a unit dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone. Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.",
    "website": "http://www.iconovo.se",
    "zipcode": "223 81"
  },
  "IDOGEN.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Idogen AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Idogen AB",
    "state": null,
    "summary": "Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, or the body's own cells or tissues in Sweden. Its advanced product candidate is IDO 8, designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII. The company also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection; and IDO AID for severe and rare autoimmune diseases. The company was founded in 2008 and is headquartered in Lund, Sweden.",
    "website": "http://www.idogen.com",
    "zipcode": "223 81"
  },
  "IMMNOV.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Diagnostics & Research",
    "long_name": "Immunovia AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Immunovia AB",
    "state": null,
    "summary": "Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.",
    "website": "http://www.immunovia.com",
    "zipcode": "223 63"
  },
  "IMMU.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Immunicum AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Immunicum AB",
    "state": null,
    "summary": "Immunicum AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trial for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as has completed Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I ALISON clinical trial for the treatment of ovarian cancers. It has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study; and research collaboration with Icahn School of Medicine At Mount Sinai. The company is headquartered in Stockholm, Sweden.",
    "website": "http://immunicum.se",
    "zipcode": "114 42"
  },
  "INDEX.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "InDex Pharmaceuticals Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "InDex Pharmaceuticals Holding A",
    "state": null,
    "summary": "InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in late stage clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in discovery stage for use in the treatment of various immunological diseases. InDex Pharmaceuticals Holding AB (publ) was founded in 2015 and is headquartered in Solna, Sweden.",
    "website": "http://www.indexpharma.com",
    "zipcode": "171 65"
  },
  "INTEG-B.ST": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Integrum AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Integrum AB ser. B",
    "state": null,
    "summary": "Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company offers OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) implant system, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system provides protection to the patient by avoiding bone fractures from accidental loads. The company also offers Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. The company was founded in 1962 and is based in MÃ¶lndal, Sweden.",
    "website": "http://www.integrum.se",
    "zipcode": "431 37"
  },
  "IRLAB-A.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "IRLAB Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IRLAB Therapeutics AB ser. A",
    "state": null,
    "summary": "IRLAB Therapeutics AB (publ), a research and development company, develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; Pirepemat, which is in phase II clinical trial for the treatment of Postural dysfunction. It also develops IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing. In addition, the company develops P003, a research project that develops drugs as a substitute of levodopa for Parkinson's disease. The company is based in Gothenburg, Sweden.",
    "website": "http://www.irlab.se",
    "zipcode": "413 46"
  },
  "IRRAS.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "IRRAS AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IRRAS AB",
    "state": null,
    "summary": "IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. It designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. The company offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. It also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include Hummingbird Quad ICP monitoring with drainage (H610), and Hummingbird Solo ICP monitoring (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. The company markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was incorporated in 2011 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.irras.com",
    "zipcode": "111 20"
  },
  "ISOFOL.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Isofol Medical AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Isofol Medical AB",
    "state": null,
    "summary": "Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, Solasia Pharma KK, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.",
    "website": "http://isofolmedical.com",
    "zipcode": "413 46"
  },
  "ISR.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "ISR Immune System Regulation Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ISR Immune System Regulation Ho",
    "state": null,
    "summary": "ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden. The company's product candidates include ISR048 that has completed Phase I/IIa clinical trial for the treatment of human immunodeficiency virus infection (HIV); and ISR049, which is in the development stage to treat HIV. It is also developing a second line of chemical entities, including ISR050 that has immunostimulatory properties. The company is headquartered in Stockholm, Sweden.",
    "website": "http://israb.se",
    "zipcode": "113 40"
  },
  "ITECH.ST": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "I-Tech AB",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "I-Tech AB",
    "state": null,
    "summary": "I-Tech AB, a bio-technology company, develops and commercializes fouling prevention products in Sweden. The company offers Selektope, a bio-repellent ingredient for marine coatings that provide hard fouling prevention for ships. It serves marine coatings manufacturers. The company was founded in 2000 and is based in MÃ¶lndal, Sweden.",
    "website": "http://www.i-tech.se",
    "zipcode": "431 83"
  },
  "IVACC.ST": {
    "city": "HÃ¤gersten",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Intervacc AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Intervacc AB",
    "state": null,
    "summary": "Intervacc AB (publ), a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. It offers vaccines, pharmaceuticals, and vitamins for horses, piglets, and cows. The company also provides veterinary bacteriological and mycological analyses for veterinarians and animal hospitals. It serves customers in Nordic countries and the Baltic states. Intervacc AB (publ) holds an agreement with the Swedish University of Agricultural Sciences, SLU for the development of animal health vaccines. The company is based in HÃ¤gersten, Sweden.",
    "website": "http://www.intervacc.se",
    "zipcode": "129 44"
  },
  "IZAFE-B.ST": {
    "city": "LidingÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "iZafe Group AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "iZafe Group AB ser. B",
    "state": null,
    "summary": "iZafe Group AB (publ) engages in the research, development, and marketing of digital medical solutions and services for medication management at home. It provides Dosell, a digital medication-dispensing robot that reduces the risk of medication errors at home. It serves consumers, and public and private-sector care providers in Sweden, the Nordic region, and internationally. The company was formerly known as MediRÃ¤tt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is based in LidingÃ¶, Sweden.",
    "website": "http://www.izafe.se",
    "zipcode": "114 46"
  },
  "KA6N.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Karo Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "KARO PHARMA AB  O.N.",
    "state": null,
    "summary": "Karo Pharma AB (publ) develops and markets prescription drugs, over-the-counter products, medical devices, and hospital supply products for pharmacies and the health care sectors in Sweden, Norway, Denmark, Finland, France, rest of Europe, the United States, and internationally. It offers dermatology products under the Decubal, Fungobase, indy beauty, Lucobase, Mildison, OLIVA, PoxClin, and PROPYLESS brands; intimate care products under the HemoClin, Multi-Gyn, Multi-Mam, Pevaryl, and Scheriproct brand names; and foot care products under the CCS, Cortimyk, Footner, Nailner, Pevaryl, and wortie brands. The company also provides pain, cough, cold products under the Bronkyl, Dolerin, Ibux, Mollipect, Nazamer, nozoil, Paracet, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Selexid brands; and wellness products under the Flux, AllÃ©vo, Dosett, Dax, antibac, BAMSE, Betavivo, and Lactocare brands. It sells its products to pharmacies and retailers through direct sales organisations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is based in Stockholm, Sweden.",
    "website": "http://www.karopharma.com",
    "zipcode": "111 22"
  },
  "KAN.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Kancera AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Kancera AB",
    "state": null,
    "summary": "Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567 and KAND145 which block the Fractalkine receptor CX3CR1 and thus specific parts of the immune system for treatment of hyperinflammation HDAC6 for the treatment of nerve inflammation and pain; and ROR inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.",
    "website": "http://www.kancera.com",
    "zipcode": "171 65"
  },
  "KARO.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Karo Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Karo Pharma AB",
    "state": null,
    "summary": "Karo Pharma AB (publ) develops and markets prescription drugs, over-the-counter products, medical devices, and hospital supply products for pharmacies and the health care sectors in Sweden, Norway, Denmark, Finland, France, rest of Europe, the United States, and internationally. It offers dermatology products under the Decubal, Fungobase, indy beauty, Lucobase, Mildison, OLIVA, PoxClin, and PROPYLESS brands; intimate care products under the HemoClin, Multi-Gyn, Multi-Mam, Pevaryl, and Scheriproct brand names; and foot care products under the CCS, Cortimyk, Footner, Nailner, Pevaryl, and wortie brands. The company also provides pain, cough, cold products under the Bronkyl, Dolerin, Ibux, Mollipect, Nazamer, nozoil, Paracet, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Selexid brands; and wellness products under the Flux, AllÃ©vo, Dosett, Dax, antibac, BAMSE, Betavivo, and Lactocare brands. It sells its products to pharmacies and retailers through direct sales organisations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is based in Stockholm, Sweden.",
    "website": "http://www.karopharma.com",
    "zipcode": "111 22"
  },
  "KDEV.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Karolinska Development AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Karolinska Development AB ser.B",
    "state": null,
    "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.karolinskadevelopment.com",
    "zipcode": "17165"
  },
  "KLAR.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Klaria Pharma Holding AB (publ.)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Klaria Pharma Holding AB",
    "state": null,
    "summary": "Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.",
    "website": "http://www.klaria.com",
    "zipcode": "754 50"
  },
  "KONT.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Health Information Services",
    "long_name": "Kontigo Care AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Kontigo Care AB",
    "state": null,
    "summary": "Kontigo Care AB (publ) provides health care solutions for addiction treatment in Sweden. It offers Previct Alcohol, a digital medical device for the drug rehabilitation; and Previct Gambling, a digital tool for the treatment and prevention of work at the gaming addiction. Kontigo Care AB (publ) was founded in 2013 and is based in Uppsala, Sweden.",
    "website": "http://www.kontigocare.com",
    "zipcode": null
  },
  "L7R.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Lipidor AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIPIDOR AB",
    "state": null,
    "summary": "Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, and AKP-03 AKP-07 for eczema. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. The company has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. Lipidor AB (publ) was founded in 2009 and is based in Stockholm, Sweden.",
    "website": "http://lipidor.se",
    "zipcode": "106 91"
  },
  "LC8A.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Calliditas Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CALLIDITAS THERAP. AD 1/2",
    "state": null,
    "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a novel oral formulation of budesonide potent local immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.calliditas.se",
    "zipcode": "111 22"
  },
  "LIDDS.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "LIDDS AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIDDS AB",
    "state": null,
    "summary": "LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an antibody-based immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.",
    "website": "http://www.liddspharma.com",
    "zipcode": "754 50"
  },
  "LIPI.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - General",
    "long_name": "Lipidor AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Lipidor AB",
    "state": null,
    "summary": "Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, and AKP-03 AKP-07 for eczema. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. The company has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. Lipidor AB (publ) was founded in 2009 and is based in Stockholm, Sweden.",
    "website": "http://lipidor.se",
    "zipcode": "106 91"
  },
  "LIPUM.ST": {
    "city": "UmeÃ¥",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Lipum AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Lipum AB",
    "state": null,
    "summary": "Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. The company was founded in 2010 and is headquartered in UmeÃ¥, Sweden.",
    "website": "http://www.lipum.se",
    "zipcode": "907 36"
  },
  "LPGO.ST": {
    "city": "UmeÃ¥",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Lipigon Pharmaceuticals AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Lipigon Pharmaceuticals AB",
    "state": null,
    "summary": "Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) was founded in 2010 and is based in UmeÃ¥, Sweden.",
    "website": "http://www.lipigon.se",
    "zipcode": "90736"
  },
  "LS6.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Clinical Laserthermia Systems AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CLINICAL LASERTHERM.SYS B",
    "state": null,
    "summary": "Clinical Laserthermia Systems AB (publ) develops and markets therapies, systems, and single-use instruments for thermal treatment of solid cancer tumors in Sweden. The company offers TRANBERG, a cancer immunotherapy system that includes a laser unit with unique monitoring capabilities and tailored single-use products primarily developed for imILT treatment; and applicator kit. It also is developing products for the treatment of breast, pancreatic, skin, and prostate cancers, as well as other solid cancer tumors. Clinical Laserthermia Systems AB (publ) has a collaboration agreement with Image Guided Therapy SA to develop and commercialize a software product for MR-generated temperature monitoring; collaborative license and co-development agreement with MRI Interventions, Inc. to provide navigation and laser ablation platforms for use in spine and neurosurgery; and clinical trial collaboration with Toronto General Hospital regarding MRI-guided laser ablation treatment of prostate cancer. The company is headquartered in Lund, Sweden.",
    "website": "http://www.clinicallaser.se",
    "zipcode": "223 81"
  },
  "LUR.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Luxbright AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LUXBRIGHT AB",
    "state": null,
    "summary": "Luxbright AB, a technology company, develops and commercializes X-ray tubes, generators, and other X-ray systems to system suppliers. The company was founded in 2012 and is based in Gothenburg, Sweden.",
    "website": "http://luxbright.com",
    "zipcode": "41346"
  },
  "LXB.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Luxbright AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Luxbright AB",
    "state": null,
    "summary": "Luxbright AB, a technology company, develops and commercializes X-ray tubes, generators, and other X-ray systems to system suppliers. The company was founded in 2012 and is based in Gothenburg, Sweden.",
    "website": "http://luxbright.com",
    "zipcode": "41346"
  },
  "M02.SG": {
    "city": "LidingÃ¶",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Medical Instruments & Supplies",
    "long_name": "iZafe Group AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IZafe Group AB Namn-Aktier B o.",
    "state": null,
    "summary": "iZafe Group AB (publ) engages in the research, development, and marketing of digital medical solutions and services for medication management at home. It provides Dosell, a digital medication-dispensing robot that reduces the risk of medication errors at home. It serves consumers, and public and private-sector care providers in Sweden, the Nordic region, and internationally. The company was formerly known as MediRÃ¤tt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is based in LidingÃ¶, Sweden.",
    "website": "http://www.izafe.se",
    "zipcode": "114 46"
  },
  "MAGLE.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Magle Chemoswed Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Magle Chemoswed Holding AB",
    "state": null,
    "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in MalmÃ¶, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.",
    "website": "http://www.maglechemoswed.cow",
    "zipcode": "212 15"
  },
  "MB8A.F": {
    "city": "Bromma",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Moberg Pharma AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MOBERG PHARMA AB",
    "state": null,
    "summary": "Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phase III clinical trial for the treatment of nail fungus treatment; and BUPI, a lozenge with bupivacaine intended for pain relief in association with inflammation and ulceration of the oral mucous membranes. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was founded in 2006 and is headquartered in Bromma, Sweden.",
    "website": "http://www.mobergpharma.se",
    "zipcode": "167 51"
  },
  "MCOV-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Care Facilities",
    "long_name": "Medicover AB (publ)",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Medicover AB ser. B",
    "state": null,
    "summary": "Medicover AB (publ) provides healthcare and diagnostic services in Germany, Germany, Romania, Ukraine, Poland, Belarus, Moldova, Serbia, Turkey, Georgia, Bulgaria, Sweden, India, Hungary, and internationally. It operates through two segment, Healthcare Services and Diagnostic Services. The company's diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. It offers outpatient and inpatient healthcare services, including fertility treatment centres, dental clinics, elderly care centres, eye care, and skin and wellness centres, as well as fitness and pharmacy solutions. The company operates 97 clinical laboratories, 733 blood-drawing points, and 26 clinics in 10 countries; and 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. It serves corporate and private customers, and patients, as well as public payers. The company was founded in 1995 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.medicover.com",
    "zipcode": "102 46"
  },
  "MN2.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Mentice AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MENTICE AB  SK -,20",
    "state": null,
    "summary": "Mentice AB (publ) provides endovascular simulation solutions to the hospitals and training centers, and medical device manufacturers worldwide. The company operates through three segments: Medical Device Industry, Teaching Entities, and Healthcare systems. The company provides software modules in the areas of acute ischemic stroke intervention, aortic valve implantation, atrial septal defect and patent foramen ovale occlusion, below-the-knee intervention, cardiac rhythm management, carotid intervention, coronary angiography, coronary PRO, endovascular aortic repair, Iliac/SFA intervention, left atrial appendage occlusion, neurovascular intervention, peripheral angiography, prostatic artery embolization, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, and vascular trauma management. It offers flight simulations to physicians and clinical teams. The company's products are used to educate, train, and improve the practitioner's skills in different types of interventions and new clinical instruments. The company was founded in 1999 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.mentice.com",
    "zipcode": "411 03"
  },
  "MNTC.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Mentice AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Mentice AB",
    "state": null,
    "summary": "Mentice AB (publ) provides endovascular simulation solutions to the hospitals and training centers, and medical device manufacturers worldwide. The company operates through three segments: Medical Device Industry, Teaching Entities, and Healthcare systems. The company provides software modules in the areas of acute ischemic stroke intervention, aortic valve implantation, atrial septal defect and patent foramen ovale occlusion, below-the-knee intervention, cardiac rhythm management, carotid intervention, coronary angiography, coronary PRO, endovascular aortic repair, Iliac/SFA intervention, left atrial appendage occlusion, neurovascular intervention, peripheral angiography, prostatic artery embolization, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, and vascular trauma management. It offers flight simulations to physicians and clinical teams. The company's products are used to educate, train, and improve the practitioner's skills in different types of interventions and new clinical instruments. The company was founded in 1999 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.mentice.com",
    "zipcode": "411 03"
  },
  "MOB.ST": {
    "city": "Bromma",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Moberg Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Moberg Pharma AB",
    "state": null,
    "summary": "Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phase III clinical trial for the treatment of nail fungus treatment; and BUPI, a lozenge with bupivacaine intended for pain relief in association with inflammation and ulceration of the oral mucous membranes. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was founded in 2006 and is headquartered in Bromma, Sweden.",
    "website": "http://www.mobergpharma.se",
    "zipcode": "167 51"
  },
  "MVIR-B.ST": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Medivir AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Medivir AB ser. B",
    "state": null,
    "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name; and simeprevir. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; and MIV-711, which is in phase II clinical trial for treating osteoarthritis. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.",
    "website": "http://www.medivir.com",
    "zipcode": "141 22"
  },
  "MVR.F": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Medivir AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDIVIR AB B  SK 10",
    "state": null,
    "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name; and simeprevir. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; and MIV-711, which is in phase II clinical trial for treating osteoarthritis. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.",
    "website": "http://www.medivir.com",
    "zipcode": "141 22"
  },
  "NANEXA.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Nanexa AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Nanexa AB",
    "state": null,
    "summary": "Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.",
    "website": "http://www.nanexa.com",
    "zipcode": "75450"
  },
  "NEVPF": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Abliva AB (publ)",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ABLIVA AB",
    "state": null,
    "summary": "Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://abliva.com",
    "zipcode": "223 81"
  },
  "NTP.F": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Abliva AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ABLIVA AB AK",
    "state": null,
    "summary": "Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
    "website": "http://abliva.com",
    "zipcode": "223 81"
  },
  "NXTCL.ST": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "NextCell Pharma AB",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NextCell Pharma AB",
    "state": null,
    "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.",
    "website": "http://www.nextcellpharma.com",
    "zipcode": "141 57"
  },
  "OASM.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Oasmia Pharmaceutical AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Oasmia Pharmaceutical AB",
    "state": null,
    "summary": "Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer. Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel that has completed pre-clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer. The company also provides combination therapies, such as XR-19 for various forms of cancer, including ovarian, first-line breast, prostate, and lung cancer. In addition, its animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.oasmia.com",
    "zipcode": "752 28"
  },
  "OASMY": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Oasmia Pharmaceutical AB (publ)",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OASMIA PHARMACEUTICAL AB SPON A",
    "state": null,
    "summary": "Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer. Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel that has completed pre-clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer. The company also provides combination therapies, such as XR-19 for various forms of cancer, including ovarian, first-line breast, prostate, and lung cancer. In addition, its animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.oasmia.com",
    "zipcode": "752 28"
  },
  "OLK": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Diagnostics & Research",
    "long_name": "Olink Holding AB (publ)",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Olink Holding AB (publ)",
    "state": null,
    "summary": "Olink Holding AB (publ) provides various products and services for academic, government, biopharmaceutical, biotechnology, and other institutions focused on life science research. Its products include Olink Explore for cardiovascular and metabolic diseases, oncology, neurology, or inflammation; Olink Target product line; and Olink Focus product line consists of custom developed solutions for customers that have identified a small number of proteins of interest to focus on. The company's products also comprise Olink NPX Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of normalized protein expression (NPX) data. In addition, it provides Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. The company sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2016 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.olink.com",
    "zipcode": "751 83"
  },
  "ONCO.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Oncopeptides AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Oncopeptides AB",
    "state": null,
    "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.oncopeptides.se",
    "zipcode": "111 53"
  },
  "ONCOZ.ST": {
    "city": "Bromma",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "OncoZenge AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OncoZenge AB",
    "state": null,
    "summary": "OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).",
    "website": "http://www.oncozenge.se",
    "zipcode": "167 51"
  },
  "OND.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Oncopeptides AB (publ)",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ONCOPEPTIDES AB O.N.",
    "state": null,
    "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.oncopeptides.se",
    "zipcode": "111 53"
  },
  "ORTI-A.ST": {
    "city": "Danderyd",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Ortivus AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Ortivus AB ser. A",
    "state": null,
    "summary": "Ortivus AB (publ) develops and commercializes medical technology solutions for healthcare industry in Sweden and internationally. It offers MobiMed, a software for electronic patient records and real-time vital signs monitoring; M531, a portable measuring unit for vital signs that integrates with the MobiMed software; and PG1-1, a portable patient unit for the MobiMed software. The company also provides PM1-1, a robust patient unit designed for use with the MobiMed software; and CS-1, a carrying system for M531 measuring unit, patient unit PM1-1, and cables and sensors. In addition, it offers healthcare IT consulting services for planning, design, implementation, and integration projects; and support, implementation, and training services. The company was founded in 1985 and is headquartered in Danderyd, Sweden.",
    "website": "http://www.ortivus.com",
    "zipcode": "182 17"
  },
  "ORTI-B.ST": {
    "city": "Danderyd",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Ortivus AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Ortivus AB ser. B",
    "state": null,
    "summary": "Ortivus AB (publ) develops and commercializes medical technology solutions for healthcare industry in Sweden and internationally. It offers MobiMed, a software for electronic patient records and real-time vital signs monitoring; M531, a portable measuring unit for vital signs that integrates with the MobiMed software; and PG1-1, a portable patient unit for the MobiMed software. The company also provides PM1-1, a robust patient unit designed for use with the MobiMed software; and CS-1, a carrying system for M531 measuring unit, patient unit PM1-1, and cables and sensors. In addition, it offers healthcare IT consulting services for planning, design, implementation, and integration projects; and support, implementation, and training services. The company was founded in 1985 and is headquartered in Danderyd, Sweden.",
    "website": "http://www.ortivus.com",
    "zipcode": "182 17"
  },
  "ORX.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Orexo AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Orexo AB",
    "state": null,
    "summary": "Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.orexo.com",
    "zipcode": "754 50"
  },
  "ORXOY": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Orexo AB (publ)",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "OREXO AB",
    "state": null,
    "summary": "Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.orexo.com",
    "zipcode": "754 50"
  },
  "OSSD.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "OssDsign AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OssDsign AB",
    "state": null,
    "summary": "OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. Its products include OSSDSIGN cranial, an implant solution for cranioplasty patients, as well as related accessories; OSSDSIGN facial to treat patients with complex facial skeletal defects; and OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage, as well as nanosynthetic bone graft substitute for treating skeletal defect. The company was incorporated in 2011 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.ossdsign.com",
    "zipcode": "754 50"
  },
  "P0F.F": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Egetis Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EGETIS THERAPEUTICS AB",
    "state": null,
    "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was founded in 2006 and is based in Stockholm, Sweden.",
    "website": "http://www.egetis.com",
    "zipcode": "114 46"
  },
  "P0F.SG": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "Egetis Therapeutics AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EGETIS THERAPEUTICS AB",
    "state": null,
    "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was founded in 2006 and is based in Stockholm, Sweden.",
    "website": "http://www.egetis.com",
    "zipcode": "114 46"
  },
  "P75.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Pharmacolog i Uppsala AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMACOLOG I UPPSALA AB",
    "state": null,
    "summary": "Pharmacolog i Uppsala AB (publ) develops systems and solutions for use of intravenous drugs in Sweden. The company offers DrugLog, a solution for reducing errors in the drug administration process; WasteLog, an integrated system to monitor and safeguard discarded narcotics from surgical procedures; and PerpLog, a DrugLog based technology platform that integrated prescription software or medication management system for the test of end result. The company was founded in 2007 and is based in Uppsala, Sweden.",
    "website": "http://www.pharmacolog.com",
    "zipcode": "752 75"
  },
  "PAPI.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Health Information Services",
    "long_name": "Papilly AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Papilly AB",
    "state": null,
    "summary": "Papilly AB (publ) operates as a healthcare company that provides Internet-based health services in Sweden. The company offers solutions for stress-related disorders. It also provides support services to the therapists who work with stress, cardiovascular disease, anxiety, relationship problems, etc. The company was formerly known as Stresscompany AB (publ) and changed its name to Papilly AB (publ) in May 2015. Papilly AB (publ) is based in Stockholm, Sweden.",
    "website": "http://www.papilly.com",
    "zipcode": "114 40"
  },
  "PAX.ST": {
    "city": "Karlshamn",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Paxman AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Paxman AB",
    "state": null,
    "summary": "Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North and South America, Central America, Asia, and Oceania. It serves various cancer centers and hospitals. Paxman AB (Publ) has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. The company was founded in 1996 and is headquartered in Karlshamn, Sweden.",
    "website": "http://www.paxman.se",
    "zipcode": "374 35"
  },
  "PGO.F": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Prostatype Genomics AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PROSTATYPE GENOMICS AB",
    "state": null,
    "summary": "Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype, a gene test for prostate cancer patients. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.",
    "website": "http://www.prostatypegenomics.com",
    "zipcode": "171 48"
  },
  "PHARM.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Pharmiva AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Pharmiva AB",
    "state": null,
    "summary": "Pharmiva AB (publ) engages in the research and development of medical products. The company develops Vernivia, an over-the-counter vaginal mousse for the treatment of bacterial vaginosis. The company is based in Lund, Sweden.",
    "website": "http://www.pharmiva.com",
    "zipcode": "22270"
  },
  "PHLOG-B.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Pharmacolog i Uppsala AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Pharmacolog i Uppsala AB ser. B",
    "state": null,
    "summary": "Pharmacolog i Uppsala AB (publ) develops systems and solutions for use of intravenous drugs in Sweden. The company offers DrugLog, a solution for reducing errors in the drug administration process; WasteLog, an integrated system to monitor and safeguard discarded narcotics from surgical procedures; and PerpLog, a DrugLog based technology platform that integrated prescription software or medication management system for the test of end result. The company was founded in 2007 and is based in Uppsala, Sweden.",
    "website": "http://www.pharmacolog.com",
    "zipcode": "752 75"
  },
  "PLUN.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Care Facilities",
    "long_name": "ProstaLund AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ProstaLund AB",
    "state": null,
    "summary": "ProstaLund AB (publ) develops and sells urological devices for the treatment of patients with benign prostatic hyperplasia (BPH) in Sweden and internationally. The company also offers CoreTherm, a heat treatment of BPH; and Gepan instill for the treatment of chronic bladder inflammation. Its products are used in hospitals and clinics. The company was founded in 1991 and is based in Lund, Sweden. ProstaLund AB (publ) is a subsidiary of Farstorps Gard Forvaltnings AB.",
    "website": "http://www.prostalund.se",
    "zipcode": "223 62"
  },
  "PQX1.F": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Biotage AB",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "BIOTAGE AB  SK 1",
    "state": null,
    "summary": "Biotage AB (publ), a life science company, provides separation technologies in the areas of organic and analytical chemistry, biomolecules, as well as for industrial scale up applications. It offers sample preparation solutions; horizon food and environmental products; microwave synthesis solutions; peptide synthesis and purification solutions; flash purification products; work-up products; evaporation and concentration solutions; and industrial and large scale products, such as flash purification, metal scavenging, reagents and scavengers, and custom resins. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, government authorities, and academic institutions; and commercial labs, hospital, CROs, bio-analytical laboratories, food manufacturers, and labs performing for food safety and environmental analysis. It operates in North and South America, Europe, Japan, China, South Korea, India, the Middle East, Africa, and Asia Pacific. The company was founded in 1969 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.biotage.com",
    "zipcode": "751 03"
  },
  "PROB.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Probi AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Probi AB",
    "state": null,
    "summary": "Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. It conducts research primarily in the fields of gastrointestinal and immune health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. The company provides dietary supplement, and food and beverage products in the form of capsules, tablets, chewable tablets, spheres, fast melt sticks, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. It sells its products approximately in 40 countries worldwide. Probi AB (publ) has a collaboration with Ãrebro University for research into exploration of novel, needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian female population. The company was founded in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.",
    "website": "http://www.probi.com",
    "zipcode": "223 70"
  },
  "PROGEN.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Diagnostics & Research",
    "long_name": "Prostatype Genomics AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Prostatype Genomics AB",
    "state": null,
    "summary": "Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype, a gene test for prostate cancer patients. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.",
    "website": "http://www.prostatypegenomics.com",
    "zipcode": "171 48"
  },
  "PROMO.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Promore Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Promore Pharma AB",
    "state": null,
    "summary": "Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand, which is in Phase III trial; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers and for the treatment of diabetic foot ulcers. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is based in Solna, Sweden.",
    "website": "http://www.promorepharma.com",
    "zipcode": "171 65"
  },
  "PXMBF": {
    "city": "Karlshamn",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Paxman AB (publ)",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PAXMAN AB",
    "state": null,
    "summary": "Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North and South America, Central America, Asia, and Oceania. It serves various cancer centers and hospitals. Paxman AB (Publ) has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. The company was founded in 1996 and is headquartered in Karlshamn, Sweden.",
    "website": "http://www.paxman.se",
    "zipcode": "374 35"
  },
  "QLIFE.ST": {
    "city": "Helsingborg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Qlife Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "QLife Holding AB",
    "state": null,
    "summary": "Qlife Holding AB (publ), a high-tech medical device company, manufactures and sells in-vitro diagnostic analyzers and reagents. It offers Egoo Home System, an integrated platform consisting of a small home device and disposable capsules each of that test for a specific biomarker, as well as a digital infrastructure that shares data with patient journal or hospital platform. The company has a research agreement with NordsjÃ¦llands Hospital to continue the validation of the Egoo Sars-CoV-2 virus test. The company was founded in 2019 and is based in Helsingborg, Sweden.",
    "website": "http://qlifeholding.com/en",
    "zipcode": "252 21"
  },
  "QLINEA.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Q-linea AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Q-Linea AB",
    "state": null,
    "summary": "Q-linea AB (publ), an innovative infection diagnostics company, researches, develops, manufactures, and sells instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was founded in 2008 and is headquartered in Uppsala, Sweden.",
    "website": "http://www.qlinea.com",
    "zipcode": "752 37"
  },
  "QUIA.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "QuiaPEG Pharmaceuticals Holding",
    "state": null,
    "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.",
    "website": "http://www.quiapeg.com",
    "zipcode": "171 65"
  },
  "RAY-B.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Health Information Services",
    "long_name": "RaySearch Laboratories AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RaySearch Laboratories AB ser. ",
    "state": null,
    "summary": "RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in Sweden and internationally. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, reduce OAR dose, robustness, the physician's toolbox, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomo therapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomo therapy, and electron beam radiation therapy; and RayCare, an oncology information system for the treatment of cancer comprising oncology treatment activities, including digital oncology workflows, rule-based scheduling, state-of-the-art software platform, enterprise-wide integration, adaptive therapy, RayCare flow, and data handling and machine learning. In addition, it offers RayCommand, a treatment control system that is compatible with multiple hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system, which turns patient data into insights. Further, the company provides training courses, as well as customer support services. RaySearch Laboratories AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.raysearchlabs.com",
    "zipcode": "111 34"
  },
  "REDW.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Redwood Pharma AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Redwood Pharma AB",
    "state": null,
    "summary": "Redwood Pharma AB engages in the development of ophthalmic pharmaceutical therapies for unmet market needs. The company's lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women. It uses IntelliGel, a supramolecular smart drug delivery system for development of topical formulation for ophthalmic uses, as well as for administration to the front of the eye. Redwood Pharma AB is based in Stockholm, Sweden.",
    "website": "http://www.redwoodpharma.se",
    "zipcode": "118 60"
  },
  "RLS.ST": {
    "city": "MÃ¶lndal",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "RLS Global AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "RLS Global AB",
    "state": null,
    "summary": "RLS Global AB (publ), a medical technology company, develops and sells products for the treatment of diseases in wound and dental care in Sweden. Its products include ChloraSolv that is used for the treatment of chronic foot and leg ulcers for diabetic patients; and CariSolv, a gel used for treating caries. The company was founded in 1996 and is based in MÃ¶lndal, Sweden.",
    "website": "http://rls.global",
    "zipcode": "431 53"
  },
  "RSLBF": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Health Information Services",
    "long_name": "RaySearch Laboratories AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RAYSEARCH LABORATORIES AB",
    "state": null,
    "summary": "RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in Sweden and internationally. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, reduce OAR dose, robustness, the physician's toolbox, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomo therapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomo therapy, and electron beam radiation therapy; and RayCare, an oncology information system for the treatment of cancer comprising oncology treatment activities, including digital oncology workflows, rule-based scheduling, state-of-the-art software platform, enterprise-wide integration, adaptive therapy, RayCare flow, and data handling and machine learning. In addition, it offers RayCommand, a treatment control system that is compatible with multiple hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system, which turns patient data into insights. Further, the company provides training courses, as well as customer support services. RaySearch Laboratories AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.raysearchlabs.com",
    "zipcode": "111 34"
  },
  "S21.F": {
    "city": "LinkÃ¶ping",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "S2Medical AB (publ)",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "S2MEDICAL AB B",
    "state": null,
    "summary": "S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds. It offers INSTAQRETT, a sterile single use mechanical debridement tool; EPIPROTECT SafeStop for blood stilling; Instagraft, a single-use medical device for the treatment of chronic and complicated wounds; EPIPROTECT tissue substitutes; and washable, waterproof, and self-adhesive bandages under the INSTABIND brand name. The company also distributes Silverlon dressings that deliver silver ions into the wound. In addition, it operates wound healing center under the S2Clinic name. The company was founded in 2013 and is headquartered in LinkÃ¶ping, Sweden.",
    "website": "http://www.s2m.se",
    "zipcode": "582 73"
  },
  "S2M.ST": {
    "city": "LinkÃ¶ping",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "S2Medical AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "S2Medical AB ser. B",
    "state": null,
    "summary": "S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds. It offers INSTAQRETT, a sterile single use mechanical debridement tool; EPIPROTECT SafeStop for blood stilling; Instagraft, a single-use medical device for the treatment of chronic and complicated wounds; EPIPROTECT tissue substitutes; and washable, waterproof, and self-adhesive bandages under the INSTABIND brand name. The company also distributes Silverlon dressings that deliver silver ions into the wound. In addition, it operates wound healing center under the S2Clinic name. The company was founded in 2013 and is headquartered in LinkÃ¶ping, Sweden.",
    "website": "http://www.s2m.se",
    "zipcode": "582 73"
  },
  "SCIB.ST": {
    "city": "Stockholm",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "SciBase Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Scibase Holding AB",
    "state": null,
    "summary": "SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions.in Europe and internationally. The company offers Nevisense, a point-of-care detection device for non-visual detection of malignant melanoma. It serves public hospitals and private dermatology clinics. The company has a collaboration agreement with Swiss Institute of Allergy and Asthma Research. The company was founded in 1998 and is headquartered in Stockholm, Sweden.",
    "website": "http://www.scibase.com",
    "zipcode": "172 63"
  },
  "SDOS.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "ScandiDos AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ScandiDos AB",
    "state": null,
    "summary": "ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family solution for pre treatment and at treatment dose verification covering various treatment technologies, such as VMAT, IMRT, SBRT, 4D-RT, and TomoTherapy; Delta4 Discover, a transmission detector that provides confidence and patient safety based on real time measurements; and Delta4 Phantom+, a system that offers accurate and verification of IMRT, VMAT, and TomoTherapy plans. It also provides HexaMotion, a motion management solution; Delta4DVH Anatomy, a software that verifies and analyzes the dose delivered in the patient anatomy; Delta4 Machine QA, a software to perform QA with respect to rotation, start-up behavior, and dynamic beam modulation; and Delta4 Trolley, an ergonomic solution. The company is headquartered in Uppsala, Sweden.",
    "website": "http://scandidos.com",
    "zipcode": "751 83"
  },
  "SECARE.ST": {
    "city": "MalmÃ¶",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Swedencare AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Swedencare AB",
    "state": null,
    "summary": "Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the formation of plaque and tartar; ProDen PlaqueOff dental bites, a pet dental product; ProDen PlaqueOff powder cat; ProDen PlaqueOff dental bones for dogs; ProDen PlaqueOff mini dental care bones, a chewy bone for smaller dogs; and ProDen PlaqueOff soft chews for dogs and cats. The company also provides dietary supplements for cats, dogs, and horses under the NutriScience brand, such as Glucosamine and Stomax used to renew joint cartilage, bones, muscles, ligaments, and sinews; ArthriAid for joints and mobility; KalmAid, which helps to calm nervous dogs; and OmegaAid and RevitalAid, a feed supplement used for healthy skin and coat. In addition, it develops and manufactures equine supplements, including Gastrocare used to relieve gastric pain and improve appetite; Equine Gold, which helps horse to thrive; ArthriAid used to aid horse's own natural manufacture of cartilage; and AnxiKalm, a supplement to calm excitable horses. Further, the company provides ProDen PlaqueOff teeth and gums, a natural food supplement to enhance dental hygiene and prevent tartar buildup for human. It distributes its products through pharmacies, veterinary clinics, pet shops, animal hospital, and online. Swedencare AB (publ) was incorporated in 1993 and is headquartered in MalmÃ¶, Sweden.",
    "website": "http://www.swedencare.se",
    "zipcode": "205 12"
  },
  "SECT-B.ST": {
    "city": "LinkÃ¶ping",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Sectra AB (publ)",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "SECTRA AB ser B",
    "state": null,
    "summary": "Sectra AB (publ) provides IT systems for managing medical images and patient information related to diagnostic imaging. The company's Imaging IT Solutions segment develops and sells medical IT systems and services for managing, archiving, and presenting various types of medical images and patient information, as well as for operational follow-up and radiation dose monitoring; maintenance services in the form of support and system monitoring; and consulting services related to integration, system design, data migration, and business development. Its Secure Communications segment develops and sells products and services for secure voice and data communications, and protection of society's sensitive IT infrastructure; customized encryption systems and products; and critical infrastructure, which offers security and threat analyses and system monitoring services for control systems in society's critical operations. The company's Business Innovation segment develops and sells IT systems for planning and monitoring orthopedic surgery; and products for medical education and research projects. It serves public and private healthcare providers comprising hospitals, and hospital and private clinic chains; and government agencies and defense departments. Sectra AB (publ) sells its products through its sales organizations and distribution partners in Africa, Europe, the Middle East, North America, Oceania, Southeast Asia, and Japan. The company was founded in 1978 and is headquartered in LinkÃ¶ping, Sweden.",
    "website": "http://www.sectra.com",
    "zipcode": "583 30"
  },
  "SEDANA.ST": {
    "city": "Danderyd",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Sedana Medical AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Sedana Medical AB",
    "state": null,
    "summary": "Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers AnaConDa and AnaConDa-S, which are disposable medical devices that enables the administration of volatile anesthetics; AnaConDa Syringe, a 50/60ml syringe; FlurAbsorb, a charcoal filter for removing halogenated hydrocarbon anesthetic gases, such as isoflurane or sevoflurane; FlurAbsorb-S, a filter containing activated carbon for the removal of waste anaesthetic gases; FlurAbsorb accessory kit comprising lines and connectors for connecting the filter to the ventilator and gas monitor; and FlurAbsorb and FlurAbsorb-S mount to hold the filter during scavenging of anesthetic gas. It also provides gas sampling lines to prevent anaesthetic volatile agents from leaching through the wall of the tube; and Nafion lines to reduce the accumulation of condensate in the anaesthetic gas measuring line and the water trap of the gas monitor. Sedana Medical AB (publ) was founded in 2005 and is headquartered in Danderyd, Sweden.",
    "website": "http://www.sedanamedical.com",
    "zipcode": "182 32"
  },
  "SENZA.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Diagnostics & Research",
    "long_name": "SenzaGen AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SenzaGen AB",
    "state": null,
    "summary": "SenzaGen AB markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals, complex mixtures, and cosmetic ingredients in Sweden and internationally. It offers GARDskin for predicting the ability of chemicals to induce sensitization; GARDpotency, an animal free test to subcategorize sensitizers according to CLP/GHS classifications by monitoring the expression of 50 complementary genomic biomarkers; and GARDair, an in vitro assay for the prediction of chemical respiratory sensitizers. The company also provides GARDskin medical devices. It offers services through distributors, laboratories, and licensed contract research organizations. SenzaGen AB has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was founded in 2010 and is headquartered in Lund, Sweden.",
    "website": "http://senzagen.com",
    "zipcode": "223 81"
  },
  "SEZI.ST": {
    "city": "Uppsala",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Senzime AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Senzime AB",
    "state": null,
    "summary": "Senzime AB (publ) develps and markets patient monitoring systems to monitor patients under anesthesia in Europe and the United States. The company offers TetraGraph, a TOF-monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; CliniSenz Analyzer, which detects early signs of complications; and Onzurf Probe for sampling from the surface of an organ. Senzime AB (publ) was founded in 1999 and is based in Uppsala, Sweden.",
    "website": "http://www.senzime.com",
    "zipcode": "756 51"
  },
  "SIMRIS-B.ST": {
    "city": "HammenhÃ¶g",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Simris Alg AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Simris Alg AB ser. B",
    "state": null,
    "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in HammenhÃ¶g, Sweden.",
    "website": "http://www.simrisalg.se",
    "zipcode": "276 50"
  },
  "SOBI.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Swedish Orphan Biovitrum AB (publ)",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Swedish Orphan Biovitrum AB",
    "state": null,
    "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.",
    "website": "http://www.sobi.com",
    "zipcode": "112 76"
  },
  "SPAGO.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Spago Nanomedical AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Spago Nanomedical AB",
    "state": null,
    "summary": "Spago Nanomedical AB (publ) develops nanomaterials for cancer diagnostics and treatment. It offers SpagoPix, a cancer selective MRI contrast agent; and Tumorad, a tumor selective radiation treatment. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was founded in 2007 and is based in Lund, Sweden.",
    "website": "http://spagonanomedical.se",
    "zipcode": "223 63"
  },
  "SPEC.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "SpectraCure AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SpectraCure AB",
    "state": null,
    "summary": "SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.",
    "website": "http://www.spectracure.com",
    "zipcode": "222 29"
  },
  "SPRINT.ST": {
    "city": "Huddinge",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Sprint Bioscience AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Sprint Bioscience AB",
    "state": null,
    "summary": "Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PIP4K2, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.",
    "website": "http://www.sprintbioscience.com",
    "zipcode": "141 57"
  },
  "STABL.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Stayble Therapeutics AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Stayble Therapeutics AB",
    "state": null,
    "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.",
    "website": "http://www.staybletherapeutics.se",
    "zipcode": "413 90"
  },
  "STIL.ST": {
    "city": "TorshÃ¤lla",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Stille AB",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Stille AB",
    "state": null,
    "summary": "Stille AB manufactures and sells surgical instruments in Sweden and internationally. The company offers artery and ligature clamps; artery forceps; bone cutters and rongeurs; clamps; curettes, raspatories, elevators, etc.; forceps; micro instruments; needle holder, wire twistings, and holding forceps; osteotomes, chisels, etc.; reactors and skin hooks; scissors; and other products. It also provides operating tables for ERCP / abdominal fluoroscopy, neuro / spine, pain management, urology, and vascular surgeries. The company was founded in 1841 and is headquartered in TorshÃ¤lla, Sweden. Stille AB is a subsidiary of Linc AB.",
    "website": "http://www.stille.se",
    "zipcode": "644 30"
  },
  "SUS.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Health Information Services",
    "long_name": "Surgical Science Sweden AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Surgical Science Sweden AB",
    "state": null,
    "summary": "Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim essence, a portable and ready-to-use VR simulator that fills the gap between lo-fi simulators and fully loaded VR systems; LapSim Haptic System, a force feedback technology with the graphics and cognitive instructions for an immersive, multi-sensory, and very real training experience; and LapSim Basic Skills module, which offers a portfolio of laparoscopic exercises that range from basic navigation to advanced suturing. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; and Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.surgicalscience.com",
    "zipcode": "412 50"
  },
  "SUSRF": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Health Information Services",
    "long_name": "Surgical Science Sweden AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SURGICAL SCIENCE SWEDEN AB",
    "state": null,
    "summary": "Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim essence, a portable and ready-to-use VR simulator that fills the gap between lo-fi simulators and fully loaded VR systems; LapSim Haptic System, a force feedback technology with the graphics and cognitive instructions for an immersive, multi-sensory, and very real training experience; and LapSim Basic Skills module, which offers a portfolio of laparoscopic exercises that range from basic navigation to advanced suturing. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; and Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.surgicalscience.com",
    "zipcode": "412 50"
  },
  "TOL.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Toleranzia AB",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Toleranzia AB",
    "state": null,
    "summary": "Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. The company is headquartered in Gothenburg, Sweden.",
    "website": "http://www.toleranzia.com",
    "zipcode": "411 26"
  },
  "VICO.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Vicore Pharma Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Vicore Pharma Holding AB",
    "state": null,
    "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.vicorepharma.com",
    "zipcode": "411 05"
  },
  "VITR.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Vitrolife AB (publ)",
    "market": "se_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Vitrolife AB",
    "state": null,
    "summary": "Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It offers oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also provides EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.vitrolife.com",
    "zipcode": "421 32"
  },
  "VTFN.F": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Vitrolife AB (publ)",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "VITROLIFE AB  SK 0,2",
    "state": null,
    "summary": "Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It offers oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also provides EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.vitrolife.com",
    "zipcode": "421 32"
  },
  "XBRANE.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Xbrane Biopharma AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Xbrane Biopharma AB",
    "state": null,
    "summary": "Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.",
    "website": "http://www.xbrane.com",
    "zipcode": "171 65"
  },
  "XINT.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Xintela AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Xintela AB",
    "state": null,
    "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.",
    "website": "http://www.xintela.se",
    "zipcode": "223 81"
  },
  "XSPRAY.ST": {
    "city": "Solna",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Xspray Pharma AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Xspray Pharma AB",
    "state": null,
    "summary": "Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.",
    "website": "http://www.xspraypharma.com",
    "zipcode": "169 67"
  },
  "XVIPF": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Xvivo Perfusion AB (publ)",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "XVIVO PERFUSION AB",
    "state": null,
    "summary": "Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. The company offers XVIVO Perfusion System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex-vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex, a buffered extracellular colloid-based electrolyte preservation solution; Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. Xvivo Perfusion AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.xvivoperfusion.com",
    "zipcode": "400 14"
  },
  "XVIVO.ST": {
    "city": "Gothenburg",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Medical Devices",
    "long_name": "Xvivo Perfusion AB (publ)",
    "market": "se_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Xvivo Perfusion AB",
    "state": null,
    "summary": "Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. The company offers XVIVO Perfusion System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex-vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex, a buffered extracellular colloid-based electrolyte preservation solution; Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. Xvivo Perfusion AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.",
    "website": "http://www.xvivoperfusion.com",
    "zipcode": "400 14"
  },
  "ZICC.ST": {
    "city": "Lund",
    "country": "Sweden",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Ziccum AB (publ)",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Ziccum AB",
    "state": null,
    "summary": "Ziccum AB (publ) develops dry powder preparations of biological pharmaceuticals. The company develops and commercializes LaminarPace, a spray drying technology that dries chemicals, vaccines, biologics, and drug substances at room temperature. Its dry powder biologics includes proteins, antibodies, vaccine viruses, and other products. The company was founded in 2017 and is headquartered in Lund, Sweden.",
    "website": "http://www.ziccum.com",
    "zipcode": "223 70"
  }
}
